<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &amp; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27550386</article-id><article-id pub-id-type="pmc">5215525</article-id><article-id pub-id-type="doi">10.1111/dom.12779</article-id><article-id pub-id-type="publisher-id">DOM12779</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase <styled-content style="fixed-case">II</styled-content> study examining effects on body weight and prediabetes in obese adults without diabetes</article-title><alt-title alt-title-type="right-running-head">Lundkvist et al.</alt-title><alt-title alt-title-type="left-running-head">Lundkvist et al.</alt-title></title-group><contrib-group><contrib id="dom12779-cr-0001" contrib-type="author"><name><surname>Lundkvist</surname><given-names>Per</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12779-cr-0002" contrib-type="author"><name><surname>Sjöström</surname><given-names>C. David</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom12779-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12779-cr-0003" contrib-type="author"><name><surname>Amini</surname><given-names>Sam</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12779-cr-0004" contrib-type="author"><name><surname>Pereira</surname><given-names>Maria J.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12779-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12779-cr-0005" contrib-type="author"><name><surname>Johnsson</surname><given-names>Eva</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom12779-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12779-cr-0006" contrib-type="author" corresp="yes"><name><surname>Eriksson</surname><given-names>Jan W.</given-names></name><degrees>MD, PhD</degrees><address><email>jan.eriksson@medsci.uu.se</email></address><xref ref-type="aff" rid="dom12779-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="dom12779-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Medical Sciences</named-content><institution>Uppsala University</institution><named-content content-type="city">Uppsala</named-content><country country="SE">Sweden</country></aff><aff id="dom12779-aff-0002"><label><sup>2</sup></label><institution>AstraZeneca</institution><named-content content-type="city">Gothenburg</named-content><country country="SE">Sweden</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Corresponding Author</bold>: Jan W. Eriksson MD, PhD, Department of Medical Sciences, Uppsala University, Uppsala 75185, Sweden (<email>jan.eriksson@medsci.uu.se</email>).</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2017</year></pub-date><volume>19</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/dom.2017.19.issue-1</issue-id><fpage>49</fpage><lpage>60</lpage><history><date date-type="received"><day>21</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>18</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2016 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-19-49.pdf"></self-uri><abstract id="dom12779-abs-0001"><sec id="dom12779-sec-0001"><title><offsets xml_i="5160" xml_f="5164" txt_i="11" txt_f="15">Aims</offsets></title><p id="dom12779-para-0001"><offsets xml_i="5199" xml_f="5354" txt_i="16" txt_f="171">To explore the effects of dual therapy with dapagliflozin and exenatide on body weight, body composition, glycaemic variables and systolic blood pressure (</offsets><styled-content style="fixed-case"><offsets xml_i="5389" xml_f="5392" txt_i="171" txt_f="174">SBP</offsets></styled-content><offsets xml_i="5409" xml_f="5444" txt_i="174" txt_f="209">) in obese adults without diabetes.</offsets></p></sec><sec id="dom12779-sec-0002"><title><offsets xml_i="5489" xml_f="5510" txt_i="211" txt_f="232">Materials and methods</offsets></title><p id="dom12779-para-0002"><offsets xml_i="5545" xml_f="5680" txt_i="233" txt_f="368">In this single‐centre, double‐blind trial, we randomized 50 obese adults without diabetes (aged 18–70 years; body mass index 30–45 kg/m</offsets><sup><offsets xml_i="5685" xml_f="5686" txt_i="368" txt_f="369">2</offsets></sup><offsets xml_i="5692" xml_f="5802" txt_i="369" txt_f="479">) to oral dapagliflozin 10 mg once daily plus subcutaneous long‐acting exenatide 2 mg once weekly or placebo. </offsets><styled-content style="fixed-case"><offsets xml_i="5837" xml_f="5840" txt_i="479" txt_f="482">MRI</offsets></styled-content><offsets xml_i="5857" xml_f="5984" txt_i="482" txt_f="609"> was used to assess change in body composition. Participants were instructed to follow a balanced diet and exercise moderately.</offsets></p></sec><sec id="dom12779-sec-0003"><title><offsets xml_i="6029" xml_f="6036" txt_i="611" txt_f="618">Results</offsets></title><p id="dom12779-para-0003"><offsets xml_i="6071" xml_f="6565" txt_i="619" txt_f="1113">Of 25 dapagliflozin/exenatide‐ and 25 placebo‐treated participants, 23 (92.0%) and 20 (80.0%) completed 24 weeks of treatment, respectively. At baseline, the mean participant age was 52 years, 61% were female, the mean body weight was 104.6 kg, and 73.5% of participants had prediabetes (impaired fasting glucose or impaired glucose tolerance). After 24 weeks, for dapagliflozin/exenatide versus placebo: the difference in body weight change was −4.13 kg (95% confidence interval −6.44, −1.81; </offsets><italic><offsets xml_i="6573" xml_f="6574" txt_i="1113" txt_f="1114">P</offsets></italic><offsets xml_i="6583" xml_f="6848" txt_i="1114" txt_f="1376"> &lt; .001), which was mostly attributable to adipose tissue reduction without lean tissue change; 36.0% versus 4.2% of participants achieved ≥5% body weight loss, respectively; and prediabetes was less frequent with active treatment (34.8% vs 85.0%, respectively; </offsets><italic><offsets xml_i="6856" xml_f="6857" txt_i="1376" txt_f="1377">P</offsets></italic><offsets xml_i="6866" xml_f="6896" txt_i="1377" txt_f="1404"> &lt; .01). The difference in </offsets><styled-content style="fixed-case"><offsets xml_i="6931" xml_f="6934" txt_i="1404" txt_f="1407">SBP</offsets></styled-content><offsets xml_i="6951" xml_f="7011" txt_i="1407" txt_f="1467"> change for dapagliflozin/exenatide versus placebo was −6.7 </offsets><styled-content style="fixed-case"><offsets xml_i="7046" xml_f="7051" txt_i="1467" txt_f="1472">mm Hg</offsets></styled-content><offsets xml_i="7068" xml_f="7272" txt_i="1472" txt_f="1676">. As expected, nausea and injection‐site reactions were more frequent with dapagliflozin/exenatide than with placebo. Only two and three participants, respectively, discontinued because of adverse events.</offsets></p></sec><sec id="dom12779-sec-0004"><title><offsets xml_i="7317" xml_f="7328" txt_i="1678" txt_f="1689">Conclusions</offsets></title><p id="dom12779-para-0004"><offsets xml_i="7363" xml_f="7473" txt_i="1690" txt_f="1800">Compared with placebo, dapagliflozin/exenatide dual therapy reduced body weight, frequency of prediabetes and </offsets><styled-content style="fixed-case"><offsets xml_i="7508" xml_f="7511" txt_i="1800" txt_f="1803">SBP</offsets></styled-content><offsets xml_i="7528" xml_f="7599" txt_i="1803" txt_f="1874"> over 24 weeks and was well tolerated in obese adults without diabetes.</offsets></p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12779-kwd-0001">dapagliflozin</kwd><kwd id="dom12779-kwd-0002">exenatide</kwd><kwd id="dom12779-kwd-0003">obesity</kwd><kwd id="dom12779-kwd-0004">prediabetes</kwd></kwd-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Bristol‐Myers Squibb</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Merck Sharp &amp; Dohme</funding-source></award-group></funding-group><funding-group><award-group><funding-source>NovoNordisk</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Sanofi</funding-source></award-group></funding-group><counts><fig-count count="2"></fig-count><table-count count="3"></table-count><page-count count="1"></page-count><word-count count="4754"></word-count></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12779</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>dom12779-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.0 mode:remove_FC converted:05.01.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom12779-cit-0000">
<string-name>
<surname>Lundkvist</surname>
<given-names>P</given-names>,</string-name>
<string-name>
<surname>Sjöström</surname>
<given-names>CD</given-names>
</string-name>,<string-name>
<surname>Amini</surname>
<given-names>S</given-names>,</string-name>
<string-name>
<surname>Pereira</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Johnsson</surname>
<given-names>E</given-names>
</string-name> and <string-name>
<surname>Eriksson</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Dapagliflozin oncedaily and exenatide once-weekly dual therapy: a 24-weekrandomized,placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes</article-title>,<source>Diabetes Obes Metab</source>, <year>2017</year>;<volume>19</volume>(<issue>1</issue>):<fpage>60</fpage>–<lpage>49</lpage>.</mixed-citation>
</p></notes><notes><fn-group id="dom12779-ntgp-0001"><fn id="dom12779-note-0001"><p>
<bold>Funding Information</bold> This study was supported by AstraZeneca. Julian Martins of inScience Communications, Springer Healthcare, provided medical writing support funded by AstraZeneca.</p></fn></fn-group></notes></front><body><sec id="dom12779-sec-0005"><label><offsets xml_i="10545" xml_f="10546" txt_i="1883" txt_f="1884">1</offsets></label><title><offsets xml_i="10561" xml_f="10573" txt_i="1884" txt_f="1896">INTRODUCTION</offsets></title><p id="dom12779-para-0005"><offsets xml_i="10608" xml_f="10694" txt_i="1897" txt_f="1983">Globally, more than 1.9 billion adults were overweight [body mass index (BMI) ≥25 kg/m</offsets><sup><offsets xml_i="10699" xml_f="10700" txt_i="1983" txt_f="1984">2</offsets></sup><offsets xml_i="10706" xml_f="10767" txt_i="1984" txt_f="2045">] in 2014, and of these, 600 million were obese (BMI ≥30 kg/m</offsets><sup><offsets xml_i="10772" xml_f="10773" txt_i="2045" txt_f="2046">2</offsets></sup><offsets xml_i="10779" xml_f="10781" txt_i="2046" txt_f="2048">).</offsets><xref rid="dom12779-bib-0001" ref-type="ref"><offsets xml_i="10826" xml_f="10827" txt_i="2048" txt_f="2049">1</offsets></xref><offsets xml_i="10834" xml_f="10938" txt_i="2049" txt_f="2153"> The management of obesity is challenging; dietary and lifestyle interventions are difficult to sustain,</offsets><xref rid="dom12779-bib-0002" ref-type="ref"><offsets xml_i="10983" xml_f="10984" txt_i="2153" txt_f="2154">2</offsets></xref><offsets xml_i="10991" xml_f="10993" txt_i="2154" txt_f="2156">, </offsets><xref rid="dom12779-bib-0003" ref-type="ref"><offsets xml_i="11038" xml_f="11039" txt_i="2156" txt_f="2157">3</offsets></xref><offsets xml_i="11046" xml_f="11160" txt_i="2157" txt_f="2271"> and pharmacotherapies for obesity have generally been ineffective over time, often with troublesome side effects.</offsets><xref rid="dom12779-bib-0004" ref-type="ref"><offsets xml_i="11205" xml_f="11206" txt_i="2271" txt_f="2272">4</offsets></xref><offsets xml_i="11213" xml_f="11214" txt_i="2272" txt_f="2273">
</offsets></p><p id="dom12779-para-0006"><offsets xml_i="11245" xml_f="11369" txt_i="2274" txt_f="2398">In contrast to older glucose‐lowering medications (sulphonylureas, insulin, thiazolidinediones) that cause body weight gain,</offsets><xref rid="dom12779-bib-0005" ref-type="ref"><offsets xml_i="11414" xml_f="11415" txt_i="2398" txt_f="2399">5</offsets></xref><offsets xml_i="11422" xml_f="11861" txt_i="2399" txt_f="2838"> newer treatments for type 2 diabetes (T2D) are associated with body weight loss, including selective sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors (e.g. dapagliflozin, empagliflozin) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs; e.g. exenatide, liraglutide). Their glucose‐lowering activities are blood glucose‐dependent, which minimizes hypoglycaemia, but they produce sustained body weight loss via different mechanisms.</offsets><xref rid="dom12779-bib-0006" ref-type="ref"><offsets xml_i="11906" xml_f="11907" txt_i="2838" txt_f="2839">6</offsets></xref><offsets xml_i="11914" xml_f="11916" txt_i="2839" txt_f="2841">, </offsets><xref rid="dom12779-bib-0007" ref-type="ref"><offsets xml_i="11961" xml_f="11962" txt_i="2841" txt_f="2842">7</offsets></xref><offsets xml_i="11969" xml_f="12186" txt_i="2842" txt_f="3059"> SGLT2 inhibitors reduce renal glucose reabsorption, thereby inducing glucosuria. The resulting excretion of calories and mild diuresis are associated with body weight loss and systolic blood pressure (SBP) reduction.</offsets><xref rid="dom12779-bib-0008" ref-type="ref"><offsets xml_i="12231" xml_f="12232" txt_i="3059" txt_f="3060">8</offsets></xref><offsets xml_i="12239" xml_f="12241" txt_i="3060" txt_f="3062">, </offsets><xref rid="dom12779-bib-0009" ref-type="ref"><offsets xml_i="12286" xml_f="12287" txt_i="3062" txt_f="3063">9</offsets></xref><offsets xml_i="12294" xml_f="12296" txt_i="3063" txt_f="3065">, </offsets><xref rid="dom12779-bib-0010" ref-type="ref"><offsets xml_i="12341" xml_f="12343" txt_i="3065" txt_f="3067">10</offsets></xref><offsets xml_i="12350" xml_f="12504" txt_i="3067" txt_f="3221"> GLP‐1RAs reduce body weight by decreasing food intake as a result of centrally mediated reduced appetite, with slowed gastric emptying also contributing.</offsets><xref rid="dom12779-bib-0007" ref-type="ref"><offsets xml_i="12549" xml_f="12550" txt_i="3221" txt_f="3222">7</offsets></xref><offsets xml_i="12557" xml_f="12598" txt_i="3222" txt_f="3263"> SBP reductions also occur with GLP‐1RAs.</offsets><xref rid="dom12779-bib-0011" ref-type="ref"><offsets xml_i="12643" xml_f="12645" txt_i="3263" txt_f="3265">11</offsets></xref><offsets xml_i="12652" xml_f="12653" txt_i="3265" txt_f="3266">
</offsets></p><p id="dom12779-para-0007"><offsets xml_i="12684" xml_f="12881" txt_i="3267" txt_f="3464">Body weight loss with dapagliflozin, a first‐in‐class highly selective SGLT2 inhibitor, is consistently observed among patients with T2D receiving oral dapagliflozin 10 mg once daily as monotherapy</offsets><xref rid="dom12779-bib-0012" ref-type="ref"><offsets xml_i="12926" xml_f="12928" txt_i="3464" txt_f="3466">12</offsets></xref><offsets xml_i="12935" xml_f="12982" txt_i="3466" txt_f="3513"> or with additional glucose‐lowering therapies.</offsets><xref rid="dom12779-bib-0013" ref-type="ref"><offsets xml_i="13027" xml_f="13029" txt_i="3513" txt_f="3515">13</offsets></xref><offsets xml_i="13036" xml_f="13038" txt_i="3515" txt_f="3517">, </offsets><xref rid="dom12779-bib-0014" ref-type="ref"><offsets xml_i="13083" xml_f="13085" txt_i="3517" txt_f="3519">14</offsets></xref><offsets xml_i="13092" xml_f="13094" txt_i="3519" txt_f="3521">, </offsets><xref rid="dom12779-bib-0015" ref-type="ref"><offsets xml_i="13139" xml_f="13141" txt_i="3521" txt_f="3523">15</offsets></xref><offsets xml_i="13148" xml_f="13150" txt_i="3523" txt_f="3525">, </offsets><xref rid="dom12779-bib-0016" ref-type="ref"><offsets xml_i="13195" xml_f="13197" txt_i="3525" txt_f="3527">16</offsets></xref><offsets xml_i="13204" xml_f="13206" txt_i="3527" txt_f="3529">, </offsets><xref rid="dom12779-bib-0017" ref-type="ref"><offsets xml_i="13251" xml_f="13253" txt_i="3529" txt_f="3531">17</offsets></xref><offsets xml_i="13260" xml_f="13262" txt_i="3531" txt_f="3533">, </offsets><xref rid="dom12779-bib-0018" ref-type="ref"><offsets xml_i="13307" xml_f="13309" txt_i="3533" txt_f="3535">18</offsets></xref><offsets xml_i="13316" xml_f="13420" txt_i="3535" txt_f="3639"> Mean body weight loss versus placebo, estimated from a network meta‐analysis, is −2.2 kg over 24 weeks,</offsets><xref rid="dom12779-bib-0019" ref-type="ref"><offsets xml_i="13465" xml_f="13467" txt_i="3639" txt_f="3641">19</offsets></xref><offsets xml_i="13474" xml_f="13523" txt_i="3641" txt_f="3690"> mostly accounted for by decreased body fat mass.</offsets><xref rid="dom12779-bib-0014" ref-type="ref"><offsets xml_i="13568" xml_f="13570" txt_i="3690" txt_f="3692">14</offsets></xref><offsets xml_i="13577" xml_f="13687" txt_i="3692" txt_f="3802"> Clinical data over 2 years show that body weight reduction with dapagliflozin 10 mg once daily is maintained.</offsets><xref rid="dom12779-bib-0020" ref-type="ref"><offsets xml_i="13732" xml_f="13734" txt_i="3802" txt_f="3804">20</offsets></xref><offsets xml_i="13741" xml_f="13742" txt_i="3804" txt_f="3805">
</offsets></p><p id="dom12779-para-0008"><offsets xml_i="13773" xml_f="14090" txt_i="3806" txt_f="4123">Exenatide, the first‐in‐class GLP‐1RA, is available in a subcutaneously injected extended‐release (2 mg once weekly) formulation. In patients with T2D, mean body weight reduction with exenatide 2 mg once weekly versus placebo, estimated from a mixed treatment comparison meta‐analysis, is about −1.6 kg over 24 weeks,</offsets><xref rid="dom12779-bib-0021" ref-type="ref"><offsets xml_i="14135" xml_f="14137" txt_i="4123" txt_f="4125">21</offsets></xref><offsets xml_i="14144" xml_f="14191" txt_i="4125" txt_f="4172"> mostly as a result of decreased body fat mass.</offsets><xref rid="dom12779-bib-0022" ref-type="ref"><offsets xml_i="14236" xml_f="14238" txt_i="4172" txt_f="4174">22</offsets></xref><offsets xml_i="14245" xml_f="14347" txt_i="4174" txt_f="4276"> Data from 3 and 5 years of treatment show sustained body weight loss with exenatide 2 mg once weekly.</offsets><xref rid="dom12779-bib-0023" ref-type="ref"><offsets xml_i="14392" xml_f="14394" txt_i="4276" txt_f="4278">23</offsets></xref><offsets xml_i="14401" xml_f="14403" txt_i="4278" txt_f="4280">, </offsets><xref rid="dom12779-bib-0024" ref-type="ref"><offsets xml_i="14448" xml_f="14450" txt_i="4280" txt_f="4282">24</offsets></xref><offsets xml_i="14457" xml_f="14458" txt_i="4282" txt_f="4283">
</offsets></p><p id="dom12779-para-0009"><offsets xml_i="14489" xml_f="14708" txt_i="4284" txt_f="4503">Combination therapy with agents acting via different mechanisms may be the most effective pharmacological approach to treating obesity and addressing evolutionary counter‐regulatory mechanisms that maintain body weight.</offsets><xref rid="dom12779-bib-0025" ref-type="ref"><offsets xml_i="14753" xml_f="14755" txt_i="4503" txt_f="4505">25</offsets></xref><offsets xml_i="14762" xml_f="14895" txt_i="4505" txt_f="4638"> For example, calorie loss through increased urinary glucose excretion with SGLT2 inhibitor treatment may lead to increased appetite,</offsets><xref rid="dom12779-bib-0008" ref-type="ref"><offsets xml_i="14940" xml_f="14941" txt_i="4638" txt_f="4639">8</offsets></xref><offsets xml_i="14948" xml_f="15073" txt_i="4639" txt_f="4764"> which might be countered by a GLP‐1RA. Combining these treatments seems appropriate to enhance and sustain body weight loss.</offsets></p><p id="dom12779-para-0010"><offsets xml_i="15104" xml_f="15550" txt_i="4765" txt_f="5211">The present proof‐of‐concept study examined body weight loss during dual therapy with oral dapagliflozin 10 mg once daily and subcutaneous exenatide 2 mg once weekly in obese participants without diabetes. Body composition, glycaemic control, and blood pressure were also examined. To the best of our knowledge, this is the first report of a randomized controlled trial evaluating initiation of dual therapy with an SGLT2 inhibitor and a GLP1‐RA.</offsets></p></sec><sec id="dom12779-sec-0006"><label><offsets xml_i="15595" xml_f="15596" txt_i="5213" txt_f="5214">2</offsets></label><title><offsets xml_i="15611" xml_f="15632" txt_i="5214" txt_f="5235">MATERIALS AND METHODS</offsets></title><sec id="dom12779-sec-0007"><label><offsets xml_i="15675" xml_f="15678" txt_i="5236" txt_f="5239">2.1</offsets></label><title><offsets xml_i="15693" xml_f="15722" txt_i="5239" txt_f="5268">Study design and participants</offsets></title><p id="dom12779-para-0011"><offsets xml_i="15757" xml_f="15913" txt_i="5269" txt_f="5425">In this collaborative, investigator‐sponsored, 24‐week, single‐centre, randomized, parallel‐group, double‐blind, placebo‐controlled phase IIa study (Figure </offsets><xref rid="dom12779-fig-0001" ref-type="fig"><offsets xml_i="15958" xml_f="15959" txt_i="5425" txt_f="5426">1</offsets></xref><offsets xml_i="15966" xml_f="16130" txt_i="5426" txt_f="5590">A), we evaluated the efficacy and safety of dual therapy with dapagliflozin 10 mg once daily and exenatide 2 mg once weekly in obese participants without diabetes (</offsets><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov"><offsets xml_i="16199" xml_f="16217" txt_i="5590" txt_f="5608">ClinicalTrials.gov</offsets></ext-link><offsets xml_i="16228" xml_f="16514" txt_i="5608" txt_f="5894"> identifier: NCT02313220). The study was conducted at a single centre in Sweden from December 2014 until August 2015. An optional 28‐week, open‐label extension followed, to be reported separately. Obese men and women aged 18 to 70 years, without diabetes and with a BMI of 30 to 45 kg/m</offsets><sup><offsets xml_i="16519" xml_f="16520" txt_i="5894" txt_f="5895">2</offsets></sup><offsets xml_i="16526" xml_f="16609" txt_i="5895" txt_f="5978">, were eligible for enrolment (for full inclusion/exclusion criteria, see File S1).</offsets></p><fig fig-type="Figure" xml:lang="en" id="dom12779-fig-0001" orientation="portrait" position="float"><label><offsets xml_i="16720" xml_f="16728" txt_i="5979" txt_f="5987">Figure 1</offsets></label><caption><p><offsets xml_i="16748" xml_f="16772" txt_i="5987" txt_f="6011">
A, Study design and B, </offsets><styled-content style="fixed-case"><offsets xml_i="16807" xml_f="16814" txt_i="6011" txt_f="6018">CONSORT</offsets></styled-content><offsets xml_i="16831" xml_f="17006" txt_i="6018" txt_f="6193"> flow diagram. *A profound lifestyle change, including a strict low‐carbohydrate/high‐fat diet that elevated blood ketones, and resulted in exclusion of this patient from the </offsets><styled-content style="fixed-case"><offsets xml_i="17041" xml_f="17058" txt_i="6193" txt_f="6210">full analysis set</offsets></styled-content><offsets xml_i="17075" xml_f="17076" txt_i="6210" txt_f="6211">.</offsets></p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-19-49-g002"></graphic></fig><p id="dom12779-para-0012"><offsets xml_i="17189" xml_f="17548" txt_i="6212" txt_f="6571">All participants provided written informed consent before enrolment. The protocol was approved by the Independent Regional Ethics Committee in Uppsala, Sweden, and by the Swedish Medical Products Agency. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation/Good Clinical Practice guidelines.</offsets></p><p id="dom12779-para-0013"><offsets xml_i="17579" xml_f="17735" txt_i="6572" txt_f="6728">Participants were enrolled at a screening visit 1 to 2 weeks before randomization at week 0. Thereafter, follow‐up visits occurred at weeks 4, 8, 12 and 24.</offsets></p></sec><sec id="dom12779-sec-0008"><label><offsets xml_i="17780" xml_f="17783" txt_i="6730" txt_f="6733">2.2</offsets></label><title><offsets xml_i="17798" xml_f="17824" txt_i="6733" txt_f="6759">Randomization and blinding</offsets></title><p id="dom12779-para-0014"><offsets xml_i="17859" xml_f="18389" txt_i="6760" txt_f="7287">Eligible participants were randomized 1 : 1 to receive active treatment or matching placebo using computer codes independently generated by PCG Clinical Services AB (Uppsala, Sweden) and sequentially assigned by the study investigator. Product identity was concealed using sequentially numbered containers. Random assignment to study treatment was stratified by sex and predefined to generate a study population comprising 60% women and 40% men so as to avoid the &gt;80% female enrolment rate commonly observed in obesity trials.</offsets><xref rid="dom12779-bib-0026" ref-type="ref"><offsets xml_i="18434" xml_f="18436" txt_i="7287" txt_f="7289">26</offsets></xref><offsets xml_i="18443" xml_f="18597" txt_i="7289" txt_f="7443"> For each stratum, block size was randomly either 2 or 4. All personnel remained blinded to treatment allocation codes until database lock after 24 weeks.</offsets></p></sec><sec id="dom12779-sec-0009"><label><offsets xml_i="18642" xml_f="18645" txt_i="7445" txt_f="7448">2.3</offsets></label><title><offsets xml_i="18660" xml_f="18670" txt_i="7448" txt_f="7458">Treatments</offsets></title><p id="dom12779-para-0015"><offsets xml_i="18705" xml_f="19142" txt_i="7459" txt_f="7896">All participants received training in self‐administration of a subcutaneously injected placebo microsphere preparation (no active ingredient). At randomization, participants assigned to active treatment (dapagliflozin/exenatide) received dapagliflozin 10 mg once daily taken orally each morning and exenatide 2 mg once weekly extended‐release formulation administered subcutaneously on the same day each week, at any time of day (Figure </offsets><xref rid="dom12779-fig-0001" ref-type="fig"><offsets xml_i="19187" xml_f="19188" txt_i="7896" txt_f="7897">1</offsets></xref><offsets xml_i="19195" xml_f="19555" txt_i="7897" txt_f="8257">A). Participants assigned to placebo received oral tablets matched to dapagliflozin 10‐mg tablets and self‐administered the placebo injection. First doses were given on the day of randomization after investigations were completed. Treatment compliance was assessed by quantifying the amount of investigational products returned and participant‐reported dosing.</offsets></p><p id="dom12779-para-0016"><offsets xml_i="19586" xml_f="19909" txt_i="8258" txt_f="8581">Participants were instructed to continue regular medication (e.g. antihypertensive or lipid‐lowering agents) without changing dosages and to take no new prescription or non‐prescription medications unless advised by a physician. Participants were requested to report changes in medication or dosages to study investigators.</offsets></p><p id="dom12779-para-0017"><offsets xml_i="19940" xml_f="20326" txt_i="8582" txt_f="8968">At each study visit, participants were given a standard leaflet and instructed to follow a balanced diet as per national guidelines. Participants were also advised to exercise moderately (e.g. walking 30 minutes most days); however, diet and exercise modification was not mandated or documented. To evaluate pharmacological effects, major lifestyle changes were not an aim of the study.</offsets></p></sec><sec id="dom12779-sec-0010"><label><offsets xml_i="20371" xml_f="20374" txt_i="8970" txt_f="8973">2.4</offsets></label><title><offsets xml_i="20389" xml_f="20397" txt_i="8973" txt_f="8981">Outcomes</offsets></title><sec id="dom12779-sec-0011"><label><offsets xml_i="20440" xml_f="20445" txt_i="8982" txt_f="8987">2.4.1</offsets></label><title><offsets xml_i="20460" xml_f="20468" txt_i="8987" txt_f="8995">Efficacy</offsets></title><p id="dom12779-para-0018"><offsets xml_i="20503" xml_f="20917" txt_i="8996" txt_f="9410">The primary efficacy endpoint was change in body weight (kg) from baseline (day of randomization) to 24 weeks with dapagliflozin/exenatide versus placebo. Body weight was measured using the same electronic scale (TANITA) at baseline, 4, 8, 12 and 24 weeks, with participants in light indoor clothing without shoes. The secondary efficacy endpoint was the percentage of body weight change from baseline to 24 weeks.</offsets></p><p id="dom12779-para-0019"><offsets xml_i="20948" xml_f="21170" txt_i="9411" txt_f="9633">Exploratory efficacy endpoints measured at baseline and 24 weeks included proportions of participants with ≥5% and ≥10% body weight reduction, body composition measures, glycaemic measures, SBP and waist/hip circumference.</offsets></p><p id="dom12779-para-0020"><offsets xml_i="21201" xml_f="21415" txt_i="9634" txt_f="9848">At weeks 0 and 24 MRI was conducted (File S1) to assess changes in volumes of abdominal visceral adipose tissue, abdominal subcutaneous adipose tissue, total adipose tissue, total lean tissue and liver fat content.</offsets></p><p id="dom12779-para-0021"><offsets xml_i="21446" xml_f="22141" txt_i="9849" txt_f="10544">Glycaemic measures included changes from baseline in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG), derived from blood samples taken between 07:30 and 10:30 hours after an overnight fast. A standard oral glucose tolerance test (OGTT), conducted at screening and at 24 weeks (File S1), assessed 2‐hour plasma glucose, and proportions with impaired fasting glucose (IFG; defined as an FPG ≥5.6 mmol/L, measured just before the OGTT), impaired glucose tolerance (IGT; defined as a plasma glucose value ≥7.8 mmol/L measured 120 minutes after the start of the OGTT), and prediabetes (any IFG or IGT). A dapagliflozin/placebo tablet was taken orally 30 minutes before the 24‐week OGTT.</offsets></p><p id="dom12779-para-0022"><offsets xml_i="22172" xml_f="22458" txt_i="10545" txt_f="10831">Urine dipstick tests were performed at baseline and showed no overt glucosuria. No further urinary glucose testing was undertaken until 3‐hour urine collection during the 24‐week OGTT; 24‐week urinary glucose was analysed after study completion to maintain blinding until database lock.</offsets></p><p id="dom12779-para-0023"><offsets xml_i="22489" xml_f="22697" txt_i="10832" txt_f="11040">Cardiovascular measures included change from baseline in seated SBP, diastolic blood pressure (DBP), which were both measured as the average of two readings and rounded to the nearest 1 mm Hg, and heart rate.</offsets></p></sec><sec id="dom12779-sec-0012"><label><offsets xml_i="22742" xml_f="22747" txt_i="11042" txt_f="11047">2.4.2</offsets></label><title><offsets xml_i="22762" xml_f="22768" txt_i="11047" txt_f="11053">Safety</offsets></title><p id="dom12779-para-0024"><offsets xml_i="22803" xml_f="23010" txt_i="11054" txt_f="11261">Safety and tolerability were assessed over 24 weeks by evaluating the changes from baseline in estimated glomerular filtration rate (eGFR; estimated using the Modification of Diet in Renal Disease equation),</offsets><xref rid="dom12779-bib-0027" ref-type="ref"><offsets xml_i="23055" xml_f="23057" txt_i="11261" txt_f="11263">27</offsets></xref><offsets xml_i="23064" xml_f="23706" txt_i="11263" txt_f="11905"> fasting ketones, fasting serum lipids and other laboratory variables of interest. Reports of adverse events (AEs, serious AEs, study treatment‐related AEs as assessed by the investigator, AEs leading to discontinuation of study treatment) were collected and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 18.0. Furthermore, AEs of special interest for dapagliflozin and exenatide treatment (urinary tract infections, genital infections, events related to volume reduction, changes in renal function and gastrointestinal symptomatology) were captured using prespecified lists of relevant MedDRA preferred terms.</offsets></p><p id="dom12779-para-0025"><offsets xml_i="23737" xml_f="23875" txt_i="11906" txt_f="12044">All blood and urine analyses were performed using standard assays at the Clinical Chemistry Laboratory of the Uppsala University Hospital.</offsets></p></sec></sec><sec id="dom12779-sec-0013"><label><offsets xml_i="23926" xml_f="23929" txt_i="12047" txt_f="12050">2.5</offsets></label><title><offsets xml_i="23944" xml_f="23963" txt_i="12050" txt_f="12069">Statistical methods</offsets></title><p id="dom12779-para-0026"><offsets xml_i="23998" xml_f="24522" txt_i="12070" txt_f="12594">The primary, secondary and exploratory efficacy endpoints were analysed in the full analysis set (FAS), defined as participants who received ≥1 dose of study medication during the 24‐week double‐blind treatment period, who had a baseline value and ≥1 post‐baseline value for ≥1 efficacy measure during the double‐blind period, and who were not found to have serious protocol non‐compliance. The analysis of safety used the safety analysis set, defined as all randomized participants who received ≥1 dose of study medication.</offsets></p><p id="dom12779-para-0027"><offsets xml_i="24553" xml_f="25511" txt_i="12595" txt_f="13553">For primary and secondary endpoints, least‐squares (LS) mean changes from baseline to 24 weeks and associated 95% confidence intervals (CIs) and p values for dapagliflozin/exenatide versus placebo differences were derived from a mixed model for repeated measures, with treatment, week, treatment‐by‐week interaction and sex as categorical fixed covariates, and baseline value as a continuous fixed covariate. An unstructured matrix for the within‐participant error variance‐covariance was used. A similar approach was used for changes in HbA1c, blood pressure, heart rate, eGFR and serum lipids. For MRI, FPG and fasting ketones, similar model terms were employed, but analysis of covariance was used. The significance of changes in proportions from baseline to 24 weeks for IFG and IGT was evaluated with paired McNemar tests for within‐treatment group changes and a Cochran–Mantel–Haenszel test, adjusted for treatment, for between‐treatment group changes.</offsets></p><p id="dom12779-para-0028"><offsets xml_i="25542" xml_f="25742" txt_i="13554" txt_f="13754">For sample‐size calculations, see File S1. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). CIs and p values were unadjusted for multiple comparisons.</offsets></p></sec></sec><sec id="dom12779-sec-0014"><label><offsets xml_i="25793" xml_f="25794" txt_i="13757" txt_f="13758">3</offsets></label><title><offsets xml_i="25809" xml_f="25816" txt_i="13758" txt_f="13765">RESULTS</offsets></title><sec id="dom12779-sec-0015"><label><offsets xml_i="25859" xml_f="25862" txt_i="13766" txt_f="13769">3.1</offsets></label><title><offsets xml_i="25877" xml_f="25889" txt_i="13769" txt_f="13781">Participants</offsets></title><p id="dom12779-para-0029"><offsets xml_i="25924" xml_f="26120" txt_i="13782" txt_f="13978">Of 25 participants randomized to receive dapagliflozin/exenatide and 25 randomized to receive placebo, 23 (92.0%) and 20 (80.0%) completed 24 weeks of double‐blind treatment, respectively (Figure </offsets><xref rid="dom12779-fig-0001" ref-type="fig"><offsets xml_i="26165" xml_f="26166" txt_i="13978" txt_f="13979">1</offsets></xref><offsets xml_i="26173" xml_f="26662" txt_i="13979" txt_f="14468">B). Two dapagliflozin/exenatide‐treated participants discontinued because of AEs (abdominal pain and injection‐site pruritus/mass). Three placebo‐treated participants discontinued because of AEs (skin ulcer/vasculitis, malaise and dyspnoea/fatigue). One placebo‐treated participant withdrew consent and one was excluded for protocol non‐compliance (strict low‐carbohydrate/high‐fat diet that elevated ketones, resulting in FAS exclusion). No withdrawals led to study medication unblinding.</offsets></p><p id="dom12779-para-0030"><offsets xml_i="26693" xml_f="26997" txt_i="14469" txt_f="14773">Glycaemic variables, vital signs and renal function were balanced across treatment groups at baseline; however, mean age, body weight, duration of obesity, waist circumference and body fat measures were numerically higher at baseline in the dapagliflozin/exenatide group than in the placebo group (Table </offsets><xref rid="dom12779-tbl-0001" ref-type="table-wrap"><offsets xml_i="27049" xml_f="27050" txt_i="14773" txt_f="14774">1</offsets></xref><offsets xml_i="27057" xml_f="27123" txt_i="14774" txt_f="14840">). Overall, more participants had IFG than IGT at baseline (Table </offsets><xref rid="dom12779-tbl-0001" ref-type="table-wrap"><offsets xml_i="27175" xml_f="27176" txt_i="14840" txt_f="14841">1</offsets></xref><offsets xml_i="27183" xml_f="27185" txt_i="14841" txt_f="14843">).</offsets></p><table-wrap id="dom12779-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label><offsets xml_i="27285" xml_f="27292" txt_i="14844" txt_f="14851">Table 1</offsets></label><caption><p><offsets xml_i="27312" xml_f="27354" txt_i="14851" txt_f="14893">Demographic and baseline characteristics (</offsets><styled-content style="fixed-case"><offsets xml_i="27389" xml_f="27392" txt_i="14893" txt_f="14896">FAS</offsets></styled-content><offsets xml_i="27409" xml_f="27410" txt_i="14896" txt_f="14897">)</offsets></p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"></col><col width="1*" align="char" char="(" span="1"></col><col width="1*" align="char" char="(" span="1"></col><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" id="dom12779-ent-0001" align="left" valign="bottom" rowspan="1" colspan="1"></th><th id="dom12779-ent-0002" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="27883" xml_f="27944" txt_i="14898" txt_f="14959">
Dapagliflozin 10 mg once daily + exenatide 2 mg once weekly
</offsets></th><th id="dom12779-ent-0003" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28029" xml_f="28093" txt_i="14959" txt_f="15023">
Placebo oral tablet once daily + placebo injection once weekly
</offsets></th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12779-ent-0004" align="left" valign="bottom" rowspan="1" colspan="1"></th><th id="dom12779-ent-0005" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28312" xml_f="28313" txt_i="15023" txt_f="15024">
</offsets><bold><offsets xml_i="28319" xml_f="28325" txt_i="15024" txt_f="15030">n = 25</offsets></bold><offsets xml_i="28332" xml_f="28333" txt_i="15030" txt_f="15031">
</offsets></th><th id="dom12779-ent-0006" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="28418" xml_f="28419" txt_i="15031" txt_f="15032">
</offsets><bold><offsets xml_i="28425" xml_f="28431" txt_i="15032" txt_f="15038">n = 24</offsets></bold><offsets xml_i="28438" xml_f="28439" txt_i="15038" txt_f="15039">
</offsets></th></tr></thead><tbody valign="top"><tr><td id="dom12779-ent-0007" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="28558" xml_f="28568" txt_i="15039" txt_f="15049">Age, years</offsets></td><td char="(" id="dom12779-ent-0008" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="28659" xml_f="28670" txt_i="15050" txt_f="15061">53.5 (13.5)</offsets></td><td char="(" id="dom12779-ent-0009" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="28761" xml_f="28772" txt_i="15062" txt_f="15073">50.0 (11.8)</offsets></td></tr><tr><td colspan="3" char="(" id="dom12779-ent-0010" align="left" valign="top" rowspan="1"><offsets xml_i="28872" xml_f="28882" txt_i="15074" txt_f="15084">Sex, n (%)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0011" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="28998" xml_f="29004" txt_i="15085" txt_f="15091">Female</offsets></td><td char="(" id="dom12779-ent-0012" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="29095" xml_f="29104" txt_i="15092" txt_f="15101">15 (60.0)</offsets></td><td char="(" id="dom12779-ent-0013" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="29195" xml_f="29204" txt_i="15102" txt_f="15111">15 (62.5)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0014" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="29320" xml_f="29324" txt_i="15112" txt_f="15116">Male</offsets></td><td char="(" id="dom12779-ent-0015" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="29415" xml_f="29424" txt_i="15117" txt_f="15126">10 (40.0)</offsets></td><td char="(" id="dom12779-ent-0016" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="29515" xml_f="29523" txt_i="15127" txt_f="15135">9 (37.5)</offsets></td></tr><tr><td id="dom12779-ent-0017" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="29614" xml_f="29629" txt_i="15136" txt_f="15151">Body weight, kg</offsets></td><td char="(" id="dom12779-ent-0018" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="29720" xml_f="29734" txt_i="15152" txt_f="15166">106.43 (15.55)</offsets></td><td char="(" id="dom12779-ent-0019" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="29825" xml_f="29839" txt_i="15167" txt_f="15181">102.72 (17.26)</offsets></td></tr><tr><td id="dom12779-ent-0020" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="29930" xml_f="29951" txt_i="15182" txt_f="15203">Body mass index, kg/m</offsets><sup><offsets xml_i="29956" xml_f="29957" txt_i="15203" txt_f="15204">2</offsets></sup><offsets xml_i="29963" xml_f="29964" txt_i="15204" txt_f="15205">
</offsets></td><td char="(" id="dom12779-ent-0021" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="30055" xml_f="30065" txt_i="15206" txt_f="15216">35.8 (2.9)</offsets></td><td char="(" id="dom12779-ent-0022" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="30156" xml_f="30166" txt_i="15217" txt_f="15227">35.0 (3.7)</offsets></td></tr><tr><td id="dom12779-ent-0023" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="30257" xml_f="30280" txt_i="15228" txt_f="15251">Waist circumference, cm</offsets></td><td char="(" id="dom12779-ent-0024" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="30371" xml_f="30383" txt_i="15252" txt_f="15264">117.6 (11.3)</offsets></td><td char="(" id="dom12779-ent-0025" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="30474" xml_f="30486" txt_i="15265" txt_f="15277">114.4 (12.6)</offsets></td></tr><tr><td id="dom12779-ent-0026" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="30577" xml_f="30598" txt_i="15278" txt_f="15299">Hip circumference, cm</offsets></td><td char="(" id="dom12779-ent-0027" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="30689" xml_f="30700" txt_i="15300" txt_f="15311">121.2 (7.5)</offsets></td><td char="(" id="dom12779-ent-0028" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="30791" xml_f="30802" txt_i="15312" txt_f="15323">117.6 (6.5)</offsets></td></tr><tr><td id="dom12779-ent-0029" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="30893" xml_f="30919" txt_i="15324" txt_f="15350">Duration of obesity, years</offsets></td><td char="(" id="dom12779-ent-0030" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="31010" xml_f="31021" txt_i="15351" txt_f="15362">27.3 (17.3)</offsets></td><td char="(" id="dom12779-ent-0031" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="31112" xml_f="31123" txt_i="15363" txt_f="15374">19.7 (13.5)</offsets></td></tr><tr><td colspan="3" char="(" id="dom12779-ent-0032" align="left" valign="top" rowspan="1"><offsets xml_i="31223" xml_f="31239" txt_i="15375" txt_f="15391">Body composition</offsets><xref ref-type="fn" rid="dom12779-note-0005"><offsets xml_i="31284" xml_f="31285" txt_i="15391" txt_f="15392">a</offsets></xref><offsets xml_i="31292" xml_f="31293" txt_i="15392" txt_f="15393">
</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0033" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="31409" xml_f="31445" txt_i="15394" txt_f="15430">Visceral abdominal adipose tissue, L</offsets></td><td char="(" id="dom12779-ent-0034" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="31536" xml_f="31545" txt_i="15431" txt_f="15440">6.3 (3.1)</offsets></td><td char="(" id="dom12779-ent-0035" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="31636" xml_f="31645" txt_i="15441" txt_f="15450">5.7 (2.4)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0036" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="31761" xml_f="31799" txt_i="15451" txt_f="15489">Subcutaneous abdominal adipose tissue,</offsets><xref ref-type="fn" rid="dom12779-note-0006"><offsets xml_i="31844" xml_f="31845" txt_i="15489" txt_f="15490">b</offsets></xref><offsets xml_i="31852" xml_f="31854" txt_i="15490" txt_f="15492"> L</offsets></td><td char="(" id="dom12779-ent-0037" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="31945" xml_f="31955" txt_i="15493" txt_f="15503">14.4 (3.8)</offsets></td><td char="(" id="dom12779-ent-0038" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="32046" xml_f="32056" txt_i="15504" txt_f="15514">14.0 (2.5)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0039" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="32172" xml_f="32195" txt_i="15515" txt_f="15538">Total adipose tissue, L</offsets></td><td char="(" id="dom12779-ent-0040" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="32286" xml_f="32296" txt_i="15539" txt_f="15549">57.1 (9.7)</offsets></td><td char="(" id="dom12779-ent-0041" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="32387" xml_f="32397" txt_i="15550" txt_f="15560">53.4 (7.0)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0042" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="32513" xml_f="32533" txt_i="15561" txt_f="15581">Total lean tissue, L</offsets></td><td char="(" id="dom12779-ent-0043" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="32624" xml_f="32634" txt_i="15582" txt_f="15592">42.6 (9.6)</offsets></td><td char="(" id="dom12779-ent-0044" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="32725" xml_f="32735" txt_i="15593" txt_f="15603">40.4 (9.1)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0045" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="32851" xml_f="32863" txt_i="15604" txt_f="15616">Liver fat, %</offsets></td><td char="(" id="dom12779-ent-0046" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="32954" xml_f="32965" txt_i="15617" txt_f="15628">10.9 (10.6)</offsets></td><td char="(" id="dom12779-ent-0047" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="33056" xml_f="33066" txt_i="15629" txt_f="15639">10.0 (8.5)</offsets></td></tr><tr><td colspan="3" char="(" id="dom12779-ent-0048" align="left" valign="top" rowspan="1"><offsets xml_i="33166" xml_f="33171" txt_i="15640" txt_f="15645">HbA1c</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0049" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="33287" xml_f="33295" txt_i="15646" txt_f="15654">mmol/mol</offsets></td><td char="(" id="dom12779-ent-0050" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="33386" xml_f="33396" txt_i="15655" txt_f="15665">37.2 (3.9)</offsets></td><td char="(" id="dom12779-ent-0051" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="33487" xml_f="33497" txt_i="15666" txt_f="15676">38.1 (3.3)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0052" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="33613" xml_f="33614" txt_i="15677" txt_f="15678">%</offsets></td><td char="(" id="dom12779-ent-0053" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="33705" xml_f="33715" txt_i="15679" txt_f="15689">5.6 (0.35)</offsets></td><td char="(" id="dom12779-ent-0054" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="33806" xml_f="33816" txt_i="15690" txt_f="15700">5.6 (0.30)</offsets></td></tr><tr><td id="dom12779-ent-0055" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="33907" xml_f="33918" txt_i="15701" txt_f="15712">FPG, mmol/L</offsets></td><td char="(" id="dom12779-ent-0056" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="34009" xml_f="34020" txt_i="15713" txt_f="15724">5.90 (0.63)</offsets></td><td char="(" id="dom12779-ent-0057" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="34111" xml_f="34122" txt_i="15725" txt_f="15736">5.83 (0.43)</offsets></td></tr><tr><td id="dom12779-ent-0058" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="34213" xml_f="34241" txt_i="15737" txt_f="15765">2‐h PG (during OGTT), mmol/L</offsets></td><td char="(" id="dom12779-ent-0059" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="34332" xml_f="34343" txt_i="15766" txt_f="15777">7.99 (2.25)</offsets></td><td char="(" id="dom12779-ent-0060" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="34434" xml_f="34445" txt_i="15778" txt_f="15789">7.10 (1.12)</offsets></td></tr><tr><td id="dom12779-ent-0061" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="34536" xml_f="34561" txt_i="15790" txt_f="15815">Impaired fasting glucose,</offsets><xref ref-type="fn" rid="dom12779-note-0007"><offsets xml_i="34606" xml_f="34607" txt_i="15815" txt_f="15816">c</offsets></xref><offsets xml_i="34614" xml_f="34620" txt_i="15816" txt_f="15822"> n (%)</offsets></td><td char="(" id="dom12779-ent-0062" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="34711" xml_f="34720" txt_i="15823" txt_f="15832">16 (64.0)</offsets></td><td char="(" id="dom12779-ent-0063" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="34811" xml_f="34820" txt_i="15833" txt_f="15842">17 (70.8)</offsets></td></tr><tr><td id="dom12779-ent-0064" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="34911" xml_f="34938" txt_i="15843" txt_f="15870">Impaired glucose tolerance,</offsets><xref ref-type="fn" rid="dom12779-note-0008"><offsets xml_i="34983" xml_f="34984" txt_i="15870" txt_f="15871">d</offsets></xref><offsets xml_i="34991" xml_f="34997" txt_i="15871" txt_f="15877"> n (%)</offsets></td><td char="(" id="dom12779-ent-0065" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="35088" xml_f="35097" txt_i="15878" txt_f="15887">12 (48.0)</offsets></td><td char="(" id="dom12779-ent-0066" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="35188" xml_f="35196" txt_i="15888" txt_f="15896">8 (33.3)</offsets></td></tr><tr><td colspan="3" char="(" id="dom12779-ent-0067" align="left" valign="top" rowspan="1"><offsets xml_i="35296" xml_f="35307" txt_i="15897" txt_f="15908">Vital signs</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0068" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="35423" xml_f="35433" txt_i="15909" txt_f="15919">DBP, mm Hg</offsets></td><td char="(" id="dom12779-ent-0069" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="35524" xml_f="35535" txt_i="15920" txt_f="15931">75.8 (10.6)</offsets></td><td char="(" id="dom12779-ent-0070" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="35626" xml_f="35637" txt_i="15932" txt_f="15943">77.0 (12.6)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0071" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="35753" xml_f="35763" txt_i="15944" txt_f="15954">SBP, mm Hg</offsets></td><td char="(" id="dom12779-ent-0072" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="35854" xml_f="35866" txt_i="15955" txt_f="15967">133.7 (12.7)</offsets></td><td char="(" id="dom12779-ent-0073" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="35957" xml_f="35969" txt_i="15968" txt_f="15980">133.8 (17.5)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0074" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="36085" xml_f="36100" txt_i="15981" txt_f="15996">Heart rate, bpm</offsets></td><td char="(" id="dom12779-ent-0075" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="36191" xml_f="36201" txt_i="15997" txt_f="16007">67.8 (9.5)</offsets></td><td char="(" id="dom12779-ent-0076" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="36292" xml_f="36302" txt_i="16008" txt_f="16018">67.0 (9.2)</offsets></td></tr><tr><td id="dom12779-ent-0077" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="36393" xml_f="36398" txt_i="16019" txt_f="16024">eGFR,</offsets><xref ref-type="fn" rid="dom12779-note-0009"><offsets xml_i="36443" xml_f="36444" txt_i="16024" txt_f="16025">e</offsets></xref><offsets xml_i="36451" xml_f="36464" txt_i="16025" txt_f="16038"> mL/min/1.73m</offsets><sup><offsets xml_i="36469" xml_f="36470" txt_i="16038" txt_f="16039">2</offsets></sup><offsets xml_i="36476" xml_f="36477" txt_i="16039" txt_f="16040">
</offsets></td><td char="(" id="dom12779-ent-0078" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="36568" xml_f="36579" txt_i="16041" txt_f="16052">85.0 (17.3)</offsets></td><td char="(" id="dom12779-ent-0079" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="36670" xml_f="36681" txt_i="16053" txt_f="16064">84.6 (12.1)</offsets></td></tr><tr><td id="dom12779-ent-0080" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="36772" xml_f="36795" txt_i="16065" txt_f="16088">Fasting ketones, mmol/L</offsets></td><td char="(" id="dom12779-ent-0081" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="36886" xml_f="36897" txt_i="16089" txt_f="16100">0.23 (0.11)</offsets></td><td char="(" id="dom12779-ent-0082" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="36988" xml_f="36999" txt_i="16101" txt_f="16112">0.21 (0.07)</offsets></td></tr><tr><td colspan="3" char="(" id="dom12779-ent-0083" align="left" valign="top" rowspan="1"><offsets xml_i="37099" xml_f="37111" txt_i="16113" txt_f="16125">Serum lipids</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0084" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="37227" xml_f="37252" txt_i="16126" txt_f="16151">Total cholesterol, mmol/L</offsets></td><td char="(" id="dom12779-ent-0085" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="37343" xml_f="37354" txt_i="16152" txt_f="16163">5.34 (1.00)</offsets></td><td char="(" id="dom12779-ent-0086" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="37445" xml_f="37456" txt_i="16164" txt_f="16175">5.35 (0.95)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0087" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="37572" xml_f="37595" txt_i="16176" txt_f="16199">LDL cholesterol, mmol/L</offsets></td><td char="(" id="dom12779-ent-0088" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="37686" xml_f="37697" txt_i="16200" txt_f="16211">3.52 (0.91)</offsets></td><td char="(" id="dom12779-ent-0089" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="37788" xml_f="37799" txt_i="16212" txt_f="16223">3.44 (0.89)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0090" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="37915" xml_f="37938" txt_i="16224" txt_f="16247">HDL cholesterol, mmol/L</offsets></td><td char="(" id="dom12779-ent-0091" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="38029" xml_f="38040" txt_i="16248" txt_f="16259">1.26 (0.28)</offsets></td><td char="(" id="dom12779-ent-0092" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="38131" xml_f="38142" txt_i="16260" txt_f="16271">1.26 (0.31)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0093" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="38258" xml_f="38279" txt_i="16272" txt_f="16293">Triglycerides, mmol/L</offsets></td><td char="(" id="dom12779-ent-0094" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="38370" xml_f="38381" txt_i="16294" txt_f="16305">1.40 (0.57)</offsets></td><td char="(" id="dom12779-ent-0095" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="38472" xml_f="38483" txt_i="16306" txt_f="16317">1.59 (0.59)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0096" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="38599" xml_f="38623" txt_i="16318" txt_f="16342">Free fatty acids, µmol/L</offsets></td><td char="(" id="dom12779-ent-0097" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="38714" xml_f="38722" txt_i="16343" txt_f="16351">218 (75)</offsets></td><td char="(" id="dom12779-ent-0098" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="38813" xml_f="38821" txt_i="16352" txt_f="16360">201 (43)</offsets></td></tr><tr><td id="dom12779-ent-0099" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="38912" xml_f="38932" txt_i="16361" txt_f="16381">Comorbidities, n (%)</offsets></td><td char="(" id="dom12779-ent-0100" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="39023" xml_f="39032" txt_i="16382" txt_f="16391">19 (76.0)</offsets></td><td char="(" id="dom12779-ent-0101" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="39123" xml_f="39132" txt_i="16392" txt_f="16401">17 (70.8)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0102" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="39248" xml_f="39274" txt_i="16402" txt_f="16428">Gastrointestinal disorders</offsets></td><td char="(" id="dom12779-ent-0103" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="39365" xml_f="39373" txt_i="16429" txt_f="16437">7 (28.0)</offsets></td><td char="(" id="dom12779-ent-0104" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="39464" xml_f="39472" txt_i="16438" txt_f="16446">3 (12.5)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0105" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="39588" xml_f="39613" txt_i="16447" txt_f="16472">Musculoskeletal disorders</offsets></td><td char="(" id="dom12779-ent-0106" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="39704" xml_f="39712" txt_i="16473" txt_f="16481">4 (16.0)</offsets></td><td char="(" id="dom12779-ent-0107" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="39803" xml_f="39811" txt_i="16482" txt_f="16490">6 (25.0)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0108" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="39927" xml_f="39961" txt_i="16491" txt_f="16525">Respiratory and thoracic disorders</offsets></td><td char="(" id="dom12779-ent-0109" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="40052" xml_f="40060" txt_i="16526" txt_f="16534">4 (16.0)</offsets></td><td char="(" id="dom12779-ent-0110" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="40151" xml_f="40159" txt_i="16535" txt_f="16543">6 (25.0)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0111" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="40275" xml_f="40287" txt_i="16544" txt_f="16556">Hypertension</offsets></td><td char="(" id="dom12779-ent-0112" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="40378" xml_f="40386" txt_i="16557" txt_f="16565">6 (24.0)</offsets></td><td char="(" id="dom12779-ent-0113" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="40477" xml_f="40485" txt_i="16566" txt_f="16574">4 (16.7)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0114" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="40601" xml_f="40611" txt_i="16575" txt_f="16585">Depression</offsets></td><td char="(" id="dom12779-ent-0115" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="40702" xml_f="40709" txt_i="16586" txt_f="16593">2 (8.0)</offsets></td><td char="(" id="dom12779-ent-0116" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="40800" xml_f="40807" txt_i="16594" txt_f="16601">1 (4.2)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0117" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="40923" xml_f="40948" txt_i="16602" txt_f="16627">Other endocrine disorders</offsets><xref ref-type="fn" rid="dom12779-note-0010"><offsets xml_i="40993" xml_f="40994" txt_i="16627" txt_f="16628">f</offsets></xref><offsets xml_i="41001" xml_f="41002" txt_i="16628" txt_f="16629">
</offsets></td><td char="(" id="dom12779-ent-0118" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="41093" xml_f="41101" txt_i="16630" txt_f="16638">5 (20.0)</offsets></td><td char="(" id="dom12779-ent-0119" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="41192" xml_f="41200" txt_i="16639" txt_f="16647">3 (12.5)</offsets></td></tr><tr><td id="dom12779-ent-0120" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="41291" xml_f="41322" txt_i="16648" txt_f="16679">Prior anti‐obesity medications,</offsets><xref ref-type="fn" rid="dom12779-note-0011"><offsets xml_i="41367" xml_f="41368" txt_i="16679" txt_f="16680">g</offsets></xref><offsets xml_i="41375" xml_f="41381" txt_i="16680" txt_f="16686"> n (%)</offsets></td><td char="(" id="dom12779-ent-0121" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="41472" xml_f="41480" txt_i="16687" txt_f="16695">6 (24.0)</offsets></td><td char="(" id="dom12779-ent-0122" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="41571" xml_f="41578" txt_i="16696" txt_f="16703">1 (4.2)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0123" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="41694" xml_f="41702" txt_i="16704" txt_f="16712">Orlistat</offsets></td><td char="(" id="dom12779-ent-0124" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="41793" xml_f="41801" txt_i="16713" txt_f="16721">4 (16.0)</offsets></td><td char="(" id="dom12779-ent-0125" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="41892" xml_f="41899" txt_i="16722" txt_f="16729">1 (4.2)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0126" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="42015" xml_f="42026" txt_i="16730" txt_f="16741">Sibutramine</offsets></td><td char="(" id="dom12779-ent-0127" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="42117" xml_f="42125" txt_i="16742" txt_f="16750">3 (12.0)</offsets></td><td char="(" id="dom12779-ent-0128" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="42216" xml_f="42223" txt_i="16751" txt_f="16758">0 (0.0)</offsets></td></tr><tr><td id="dom12779-ent-0129" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="42314" xml_f="42338" txt_i="16759" txt_f="16783">Concomitant medications,</offsets><xref ref-type="fn" rid="dom12779-note-0012"><offsets xml_i="42383" xml_f="42384" txt_i="16783" txt_f="16784">h</offsets></xref><offsets xml_i="42391" xml_f="42397" txt_i="16784" txt_f="16790"> n (%)</offsets></td><td char="(" id="dom12779-ent-0130" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="42488" xml_f="42497" txt_i="16791" txt_f="16800">24 (96.0)</offsets></td><td char="(" id="dom12779-ent-0131" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="42588" xml_f="42597" txt_i="16801" txt_f="16810">23 (95.8)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0132" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="42713" xml_f="42730" txt_i="16811" txt_f="16828">ARB/ACE inhibitor</offsets></td><td char="(" id="dom12779-ent-0133" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="42821" xml_f="42829" txt_i="16829" txt_f="16837">4 (16.0)</offsets></td><td char="(" id="dom12779-ent-0134" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="42920" xml_f="42928" txt_i="16838" txt_f="16846">6 (25.0)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0135" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="43044" xml_f="43053" txt_i="16847" txt_f="16856">Diuretics</offsets></td><td char="(" id="dom12779-ent-0136" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="43144" xml_f="43152" txt_i="16857" txt_f="16865">4 (16.0)</offsets></td><td char="(" id="dom12779-ent-0137" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="43243" xml_f="43250" txt_i="16866" txt_f="16873">1 (4.2)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0138" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="43366" xml_f="43393" txt_i="16874" txt_f="16901">Thyroid replacement therapy</offsets></td><td char="(" id="dom12779-ent-0139" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="43484" xml_f="43492" txt_i="16902" txt_f="16910">5 (20.0)</offsets></td><td char="(" id="dom12779-ent-0140" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="43583" xml_f="43590" txt_i="16911" txt_f="16918">2 (8.3)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0141" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="43706" xml_f="43730" txt_i="16919" txt_f="16943">Calcium channel blockers</offsets></td><td char="(" id="dom12779-ent-0142" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="43821" xml_f="43828" txt_i="16944" txt_f="16951">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0143" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="43919" xml_f="43927" txt_i="16952" txt_f="16960">3 (12.5)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0144" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="44043" xml_f="44063" txt_i="16961" txt_f="16981">Beta‐blocking agents</offsets></td><td char="(" id="dom12779-ent-0145" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="44154" xml_f="44161" txt_i="16982" txt_f="16989">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0146" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="44252" xml_f="44259" txt_i="16990" txt_f="16997">1 (4.2)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="dom12779-note-0003"><p><offsets xml_i="44333" xml_f="44348" txt_i="16998" txt_f="17013">Abbreviations: </offsets><styled-content style="fixed-case"><offsets xml_i="44383" xml_f="44386" txt_i="17013" txt_f="17016">ACE</offsets></styled-content><offsets xml_i="44403" xml_f="44436" txt_i="17016" txt_f="17049">, angiotensin converting‐enzyme; </offsets><styled-content style="fixed-case"><offsets xml_i="44471" xml_f="44474" txt_i="17049" txt_f="17052">ARB</offsets></styled-content><offsets xml_i="44491" xml_f="44523" txt_i="17052" txt_f="17084">, angiotensin receptor blocker; </offsets><styled-content style="fixed-case"><offsets xml_i="44558" xml_f="44563" txt_i="17084" txt_f="17089">NSAID</offsets></styled-content><offsets xml_i="44580" xml_f="44620" txt_i="17089" txt_f="17129">, non‐steroidal anti‐inflammatory drug; </offsets><styled-content style="fixed-case"><offsets xml_i="44655" xml_f="44657" txt_i="17129" txt_f="17131">PG</offsets></styled-content><offsets xml_i="44674" xml_f="44717" txt_i="17131" txt_f="17174">, plasma glucose; s.d., standard deviation.</offsets></p></fn><fn id="dom12779-note-0004"><p><offsets xml_i="44757" xml_f="44806" txt_i="17175" txt_f="17224">Data are mean (s.d.), unless otherwise indicated.</offsets></p></fn><fn id="dom12779-note-0005"><label><offsets xml_i="44850" xml_f="44851" txt_i="17225" txt_f="17226">a</offsets></label><p><offsets xml_i="44862" xml_f="44877" txt_i="17226" txt_f="17241">Measured using </offsets><styled-content style="fixed-case"><offsets xml_i="44912" xml_f="44915" txt_i="17241" txt_f="17244">MRI</offsets></styled-content><offsets xml_i="44932" xml_f="44933" txt_i="17244" txt_f="17245">.</offsets></p></fn><fn id="dom12779-note-0006"><label><offsets xml_i="44977" xml_f="44978" txt_i="17246" txt_f="17247">b</offsets></label><p><offsets xml_i="44989" xml_f="45092" txt_i="17247" txt_f="17350">Defined as the subcutaneous fat positioned between the hip joint and up to the lower pole of the lungs.</offsets></p></fn><fn id="dom12779-note-0007"><label><offsets xml_i="45136" xml_f="45137" txt_i="17351" txt_f="17352">c</offsets></label><p><offsets xml_i="45148" xml_f="45229" txt_i="17352" txt_f="17433">Defined as a fasting plasma glucose value ≥5.6 mmol/L measured at time = 0 of an </offsets><styled-content style="fixed-case"><offsets xml_i="45264" xml_f="45268" txt_i="17433" txt_f="17437">OGTT</offsets></styled-content><offsets xml_i="45285" xml_f="45319" txt_i="17437" txt_f="17471"> conducted at the screening visit.</offsets></p></fn><fn id="dom12779-note-0008"><label><offsets xml_i="45363" xml_f="45364" txt_i="17472" txt_f="17473">d</offsets></label><p><offsets xml_i="45375" xml_f="45458" txt_i="17473" txt_f="17556">Defined as a plasma glucose value ≥7.8 mmol/L measured at time = 120 minutes of an </offsets><styled-content style="fixed-case"><offsets xml_i="45493" xml_f="45497" txt_i="17556" txt_f="17560">OGTT</offsets></styled-content><offsets xml_i="45514" xml_f="45548" txt_i="17560" txt_f="17594"> conducted at the screening visit.</offsets></p></fn><fn id="dom12779-note-0009"><label><offsets xml_i="45592" xml_f="45593" txt_i="17595" txt_f="17596">e</offsets></label><p><offsets xml_i="45604" xml_f="45669" txt_i="17596" txt_f="17661">Assessed using the Modification of Diet in Renal Disease formula.</offsets></p></fn><fn id="dom12779-note-0010"><label><offsets xml_i="45713" xml_f="45714" txt_i="17662" txt_f="17663">f</offsets></label><p><offsets xml_i="45725" xml_f="45809" txt_i="17663" txt_f="17747">Hypothyroidism (n = 6), goiter (n = 1), and partial pituitary insufficiency (n = 1).</offsets></p></fn><fn id="dom12779-note-0011"><label><offsets xml_i="45853" xml_f="45854" txt_i="17748" txt_f="17749">g</offsets></label><p><offsets xml_i="45865" xml_f="45911" txt_i="17749" txt_f="17795">Stopped earlier than 1 month before enrolment.</offsets></p></fn><fn id="dom12779-note-0012"><label><offsets xml_i="45955" xml_f="45956" txt_i="17796" txt_f="17797">h</offsets></label><p><offsets xml_i="45967" xml_f="46046" txt_i="17797" txt_f="17876">Ongoing or started on the date of randomization or stopped after randomization.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="dom12779-sec-0016"><label><offsets xml_i="46127" xml_f="46130" txt_i="17878" txt_f="17881">3.2</offsets></label><title><offsets xml_i="46145" xml_f="46153" txt_i="17881" txt_f="17889">Efficacy</offsets></title><sec id="dom12779-sec-0017"><label><offsets xml_i="46196" xml_f="46201" txt_i="17890" txt_f="17895">3.2.1</offsets></label><title><offsets xml_i="46216" xml_f="46227" txt_i="17895" txt_f="17906">Body weight</offsets></title><p id="dom12779-para-0031"><offsets xml_i="46262" xml_f="46346" txt_i="17907" txt_f="17991">Dapagliflozin/exenatide reduced body weight significantly more than placebo (Figure </offsets><xref rid="dom12779-fig-0002" ref-type="fig"><offsets xml_i="46391" xml_f="46392" txt_i="17991" txt_f="17992">2</offsets></xref><offsets xml_i="46399" xml_f="46408" txt_i="17992" txt_f="18001">A; Table </offsets><xref rid="dom12779-tbl-0002" ref-type="table-wrap"><offsets xml_i="46460" xml_f="46461" txt_i="18001" txt_f="18002">2</offsets></xref><offsets xml_i="46468" xml_f="46651" txt_i="18002" txt_f="18185">), with a mean difference of −4.13 kg after 24 weeks. The overall percentage reduction in body weight was also significantly greater with dapagliflozin/exenatide than placebo (Figure </offsets><xref rid="dom12779-fig-0002" ref-type="fig"><offsets xml_i="46696" xml_f="46697" txt_i="18185" txt_f="18186">2</offsets></xref><offsets xml_i="46704" xml_f="46713" txt_i="18186" txt_f="18195">B; Table </offsets><xref rid="dom12779-tbl-0002" ref-type="table-wrap"><offsets xml_i="46765" xml_f="46766" txt_i="18195" txt_f="18196">2</offsets></xref><offsets xml_i="46773" xml_f="46924" txt_i="18196" txt_f="18347">), and more participants treated with dapagliflozin/exenatide than placebo achieved body weight reductions ≥5% and ≥10% of their initial weight (Table </offsets><xref rid="dom12779-tbl-0002" ref-type="table-wrap"><offsets xml_i="46976" xml_f="46977" txt_i="18347" txt_f="18348">2</offsets></xref><offsets xml_i="46984" xml_f="47127" txt_i="18348" txt_f="18491">). Similarly, more participants treated with dapagliflozin/exenatide than placebo achieved any body weight loss or no body weight gain (Figure </offsets><xref rid="dom12779-fig-0002" ref-type="fig"><offsets xml_i="47172" xml_f="47173" txt_i="18491" txt_f="18492">2</offsets></xref><offsets xml_i="47180" xml_f="47377" txt_i="18492" txt_f="18689">C,D). The rate of body weight loss with dapagliflozin/exenatide appeared to be most rapid up to 12 weeks for most participants, although some showed continuing body weight loss to 24 weeks (Figure </offsets><xref rid="dom12779-fig-0002" ref-type="fig"><offsets xml_i="47422" xml_f="47423" txt_i="18689" txt_f="18690">2</offsets></xref><offsets xml_i="47430" xml_f="47433" txt_i="18690" txt_f="18693">C).</offsets></p><fig fig-type="Figure" xml:lang="en" id="dom12779-fig-0002" orientation="portrait" position="float"><label><offsets xml_i="47544" xml_f="47552" txt_i="18694" txt_f="18702">Figure 2</offsets></label><caption><p><offsets xml_i="47572" xml_f="48007" txt_i="18702" txt_f="19137">
A, Primary endpoint: adjusted mean change from baseline in body weight (kg) over 24 weeks; B, secondary endpoint: adjusted mean percentage change from baseline in body weight (%) after 24 weeks; C, individual participant trajectories of percent change in body weight over 24 weeks in dapagliflozin/exenatide‐treated participants; D, corresponding trajectories in placebo‐treated participants; E, adjusted mean change from baseline in </offsets><styled-content style="fixed-case"><offsets xml_i="48042" xml_f="48047" txt_i="19137" txt_f="19142">HbA1c</offsets></styled-content><offsets xml_i="48064" xml_f="48138" txt_i="19142" txt_f="19216"> (mmol/mol and %) over 24 weeks; F, adjusted mean change from baseline in </offsets><styled-content style="fixed-case"><offsets xml_i="48173" xml_f="48176" txt_i="19216" txt_f="19219">FPG</offsets></styled-content><offsets xml_i="48193" xml_f="48255" txt_i="19219" txt_f="19281"> (mmol/L) after 24 weeks; G, proportions of participants with </offsets><styled-content style="fixed-case"><offsets xml_i="48290" xml_f="48293" txt_i="19281" txt_f="19284">IFG</offsets></styled-content><offsets xml_i="48310" xml_f="48415" txt_i="19284" txt_f="19389"> or impaired glucose tolerance at screening and after 24 weeks; H, adjusted mean change from baseline in </offsets><styled-content style="fixed-case"><offsets xml_i="48450" xml_f="48453" txt_i="19389" txt_f="19392">SBP</offsets></styled-content><offsets xml_i="48470" xml_f="48472" txt_i="19392" txt_f="19394"> (</offsets><styled-content style="fixed-case"><offsets xml_i="48507" xml_f="48512" txt_i="19394" txt_f="19399">mm Hg</offsets></styled-content><offsets xml_i="48529" xml_f="48961" txt_i="19399" txt_f="19831">) over 24 weeks. Analyses in panels A, B, E, and H used mixed models for repeated measures of change or percentage change from baseline adjusted for treatment, week, treatment‐by‐week, sex, and baseline value. The analysis in panel F used analysis of covariance of change from baseline adjusted for treatment, week, treatment‐by‐week, sex and baseline value. Treatment differences presented in panels A, B, E, F, and H are adjusted </offsets><styled-content style="fixed-case"><offsets xml_i="48996" xml_f="48998" txt_i="19831" txt_f="19833">LS</offsets></styled-content><offsets xml_i="49015" xml_f="49042" txt_i="19833" txt_f="19860"> mean differences with 95% </offsets><styled-content style="fixed-case"><offsets xml_i="49077" xml_f="49080" txt_i="19860" txt_f="19863">CIs</offsets></styled-content><offsets xml_i="49097" xml_f="49099" txt_i="19863" txt_f="19865">. </offsets><sup><offsets xml_i="49104" xml_f="49105" txt_i="19865" txt_f="19866">*</offsets></sup><offsets xml_i="49111" xml_f="49112" txt_i="19866" txt_f="19867">
</offsets><italic><offsets xml_i="49120" xml_f="49121" txt_i="19867" txt_f="19868">P</offsets></italic><offsets xml_i="49130" xml_f="49141" txt_i="19868" txt_f="19876"> &lt; .05; </offsets><sup><offsets xml_i="49146" xml_f="49148" txt_i="19876" txt_f="19878">**</offsets></sup><offsets xml_i="49154" xml_f="49155" txt_i="19878" txt_f="19879">
</offsets><italic><offsets xml_i="49163" xml_f="49164" txt_i="19879" txt_f="19880">P</offsets></italic><offsets xml_i="49173" xml_f="49243" txt_i="19880" txt_f="19947"> &lt; .01 (compared to baseline). The analyses in all panels used the </offsets><styled-content style="fixed-case"><offsets xml_i="49278" xml_f="49281" txt_i="19947" txt_f="19950">FAS</offsets></styled-content><offsets xml_i="49298" xml_f="49607" txt_i="19950" txt_f="20259">; in panels C and D, corresponding per‐protocol analysis set proportions within weight loss ranges at 24 weeks (weight gain, weight loss up to 4.9%, weight loss ≥5%) were 2/22 (9.1%), 11/22 (50.0%), and 9/22 (40.9%) with dapagliflozin/exenatide, and 9/20 (45.0%), 10/20 (50.0%), and 1/20 (5.0%) with placebo. </offsets><sup><offsets xml_i="49612" xml_f="49613" txt_i="20259" txt_f="20260">†</offsets></sup><offsets xml_i="49619" xml_f="49754" txt_i="20260" txt_f="20395">One of these placebo‐treated participants was diagnosed with type 2 diabetes based on American Diabetes Association plasma glucose and </offsets><styled-content style="fixed-case"><offsets xml_i="49789" xml_f="49794" txt_i="20395" txt_f="20400">HbA1c</offsets></styled-content><offsets xml_i="49811" xml_f="49849" txt_i="20400" txt_f="20438"> criteria at the final 24‐week visit. </offsets><styled-content style="fixed-case"><offsets xml_i="49884" xml_f="49886" txt_i="20438" txt_f="20440">BL</offsets></styled-content><offsets xml_i="49903" xml_f="49914" txt_i="20440" txt_f="20451">, baseline.</offsets></p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-19-49-g001"></graphic></fig><table-wrap id="dom12779-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label><offsets xml_i="50096" xml_f="50103" txt_i="20452" txt_f="20459">Table 2</offsets></label><caption><p><offsets xml_i="50123" xml_f="50184" txt_i="20459" txt_f="20520">Primary, secondary and exploratory endpoints after 24 weeks (</offsets><styled-content style="fixed-case"><offsets xml_i="50219" xml_f="50222" txt_i="20520" txt_f="20523">FAS</offsets></styled-content><offsets xml_i="50239" xml_f="50240" txt_i="20523" txt_f="20524">)</offsets></p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"></col><col width="1*" align="char" char="(" span="1"></col><col width="1*" align="char" char="(" span="1"></col><col width="1*" align="char" char="(" span="1"></col><col width="1*" align="char" char="." span="1"></col><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" id="dom12779-ent-0147" align="left" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="50734" xml_f="50735" txt_i="20525" txt_f="20526">
</offsets></th><th id="dom12779-ent-0148" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="50820" xml_f="50821" txt_i="20526" txt_f="20527">
</offsets><bold><offsets xml_i="50827" xml_f="50886" txt_i="20527" txt_f="20586">Dapagliflozin 10 mg once daily + exenatide 2 mg once weekly</offsets></bold><offsets xml_i="50893" xml_f="50894" txt_i="20586" txt_f="20587">
</offsets></th><th id="dom12779-ent-0149" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="50979" xml_f="50980" txt_i="20587" txt_f="20588">
</offsets><bold><offsets xml_i="50986" xml_f="51048" txt_i="20588" txt_f="20650">Placebo oral tablet once daily + placebo injection once weekly</offsets></bold><offsets xml_i="51055" xml_f="51056" txt_i="20650" txt_f="20651">
</offsets></th><th id="dom12779-ent-0150" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="51141" xml_f="51142" txt_i="20651" txt_f="20652">
</offsets><bold><offsets xml_i="51148" xml_f="51193" txt_i="20652" txt_f="20697">Dapagliflozin/exenatide vs placebo difference</offsets></bold><offsets xml_i="51200" xml_f="51201" txt_i="20697" txt_f="20698">
</offsets></th><th id="dom12779-ent-0151" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="51286" xml_f="51287" txt_i="20698" txt_f="20699">
</offsets><bold><italic><offsets xml_i="51301" xml_f="51302" txt_i="20699" txt_f="20700">P</offsets></italic><offsets xml_i="51311" xml_f="51317" txt_i="20700" txt_f="20706"> value</offsets></bold><offsets xml_i="51324" xml_f="51325" txt_i="20706" txt_f="20707">
</offsets></th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12779-ent-0152" align="left" valign="bottom" rowspan="1" colspan="1"></th><th id="dom12779-ent-0153" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="51544" xml_f="51545" txt_i="20707" txt_f="20708">
</offsets><bold><offsets xml_i="51551" xml_f="51559" txt_i="20708" txt_f="20716">(n = 25)</offsets></bold><offsets xml_i="51566" xml_f="51567" txt_i="20716" txt_f="20717">
</offsets></th><th id="dom12779-ent-0154" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="51652" xml_f="51653" txt_i="20717" txt_f="20718">
</offsets><bold><offsets xml_i="51659" xml_f="51667" txt_i="20718" txt_f="20726">(n = 24)</offsets></bold><offsets xml_i="51674" xml_f="51675" txt_i="20726" txt_f="20727">
</offsets></th><th id="dom12779-ent-0155" align="char" valign="bottom" rowspan="1" colspan="1"></th><th id="dom12779-ent-0156" align="char" valign="bottom" rowspan="1" colspan="1"></th></tr></thead><tbody valign="top"><tr><td colspan="5" id="dom12779-ent-0157" align="left" valign="top" rowspan="1"><offsets xml_i="51964" xml_f="51980" txt_i="20727" txt_f="20743">Primary endpoint</offsets><xref ref-type="fn" rid="dom12779-note-0015"><offsets xml_i="52025" xml_f="52026" txt_i="20743" txt_f="20744">a</offsets></xref><offsets xml_i="52033" xml_f="52034" txt_i="20744" txt_f="20745">
</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0158" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="52150" xml_f="52196" txt_i="20746" txt_f="20792">Body weight, adjusted mean change (95% CI), kg</offsets></td><td char="(" id="dom12779-ent-0159" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="52287" xml_f="52307" txt_i="20793" txt_f="20813">−4.48 (−6.08, −2.87)</offsets></td><td char="(" id="dom12779-ent-0160" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="52398" xml_f="52417" txt_i="20814" txt_f="20833">−0.35 (−2.02, 1.32)</offsets></td><td char="(" id="dom12779-ent-0161" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="52508" xml_f="52528" txt_i="20834" txt_f="20854">−4.13 (−6.44, −1.81)</offsets></td><td char="." id="dom12779-ent-0162" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="52619" xml_f="52627" txt_i="20855" txt_f="20860">&lt;.001</offsets></td></tr><tr><td colspan="5" char="." id="dom12779-ent-0163" align="left" valign="top" rowspan="1"><offsets xml_i="52727" xml_f="52745" txt_i="20861" txt_f="20879">Secondary endpoint</offsets><xref ref-type="fn" rid="dom12779-note-0015"><offsets xml_i="52790" xml_f="52791" txt_i="20879" txt_f="20880">a</offsets></xref><offsets xml_i="52798" xml_f="52799" txt_i="20880" txt_f="20881">
</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0164" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="52915" xml_f="52971" txt_i="20882" txt_f="20938">Body weight, adjusted mean percentage change (95% CI), %</offsets></td><td char="(" id="dom12779-ent-0165" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="53062" xml_f="53082" txt_i="20939" txt_f="20959">−4.47 (−6.04, −2.89)</offsets></td><td char="(" id="dom12779-ent-0166" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="53173" xml_f="53192" txt_i="20960" txt_f="20979">−0.27 (−1.92, 1.37)</offsets></td><td char="(" id="dom12779-ent-0167" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="53283" xml_f="53303" txt_i="20980" txt_f="21000">−4.19 (−6.47, −1.92)</offsets></td><td char="." id="dom12779-ent-0168" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="53394" xml_f="53402" txt_i="21001" txt_f="21006">&lt;.001</offsets></td></tr><tr><td colspan="5" char="." id="dom12779-ent-0169" align="left" valign="top" rowspan="1"><offsets xml_i="53502" xml_f="53523" txt_i="21007" txt_f="21028">Exploratory endpoints</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0170" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="53639" xml_f="53688" txt_i="21029" txt_f="21078">Body weight, proportion with ≥5% reduction, n (%)</offsets></td><td char="(" id="dom12779-ent-0171" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="53779" xml_f="53787" txt_i="21079" txt_f="21087">9 (36.0)</offsets></td><td char="(" id="dom12779-ent-0172" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="53878" xml_f="53885" txt_i="21088" txt_f="21095">1 (4.2)</offsets></td><td id="dom12779-ent-0173" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0174" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0175" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="54165" xml_f="54215" txt_i="21098" txt_f="21148">Body weight, proportion with ≥10% reduction, n (%)</offsets></td><td char="(" id="dom12779-ent-0176" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="54306" xml_f="54314" txt_i="21149" txt_f="21157">3 (12.0)</offsets></td><td char="(" id="dom12779-ent-0177" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="54405" xml_f="54412" txt_i="21158" txt_f="21165">0 (0.0)</offsets></td><td id="dom12779-ent-0178" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0179" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0180" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="54692" xml_f="54721" txt_i="21168" txt_f="21197">MRI body composition measures</offsets><xref ref-type="fn" rid="dom12779-note-0016"><offsets xml_i="54766" xml_f="54767" txt_i="21197" txt_f="21198">b</offsets></xref><offsets xml_i="54774" xml_f="54775" txt_i="21198" txt_f="21199">
</offsets></td><td id="dom12779-ent-0181" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0182" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0183" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0184" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0185" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="55219" xml_f="55286" txt_i="21204" txt_f="21271">Visceral abdominal adipose tissue, adjusted mean change (95% CI), l</offsets></td><td char="(" id="dom12779-ent-0186" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="55377" xml_f="55397" txt_i="21272" txt_f="21292">−0.40 (−0.63, −0.16)</offsets></td><td char="(" id="dom12779-ent-0187" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="55488" xml_f="55506" txt_i="21293" txt_f="21311">0.22 (−0.02, 0.46)</offsets></td><td char="(" id="dom12779-ent-0188" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="55597" xml_f="55617" txt_i="21312" txt_f="21332">−0.62 (−0.95, −0.29)</offsets></td><td char="." id="dom12779-ent-0189" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="55708" xml_f="55716" txt_i="21333" txt_f="21338">&lt;.001</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0190" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="55832" xml_f="55870" txt_i="21339" txt_f="21377">Subcutaneous abdominal adipose tissue,</offsets><xref ref-type="fn" rid="dom12779-note-0017"><offsets xml_i="55915" xml_f="55916" txt_i="21377" txt_f="21378">c</offsets></xref><offsets xml_i="55923" xml_f="55956" txt_i="21378" txt_f="21411"> adjusted mean change (95% CI), l</offsets></td><td char="(" id="dom12779-ent-0191" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="56047" xml_f="56067" txt_i="21412" txt_f="21432">−1.31 (−1.80, −0.81)</offsets></td><td char="(" id="dom12779-ent-0192" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="56158" xml_f="56176" txt_i="21433" txt_f="21451">0.13 (−0.41, 0.67)</offsets></td><td char="(" id="dom12779-ent-0193" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="56267" xml_f="56287" txt_i="21452" txt_f="21472">−1.44 (−2.16, −0.71)</offsets></td><td char="." id="dom12779-ent-0194" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="56378" xml_f="56386" txt_i="21473" txt_f="21478">&lt;.001</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0195" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="56502" xml_f="56556" txt_i="21479" txt_f="21533">Total adipose tissue, adjusted mean change (95% CI), l</offsets></td><td char="(" id="dom12779-ent-0196" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="56647" xml_f="56667" txt_i="21534" txt_f="21554">−4.22 (−5.69, −2.76)</offsets></td><td char="(" id="dom12779-ent-0197" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="56758" xml_f="56777" txt_i="21555" txt_f="21574">−0.14 (−1.72, 1.45)</offsets></td><td char="(" id="dom12779-ent-0198" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="56868" xml_f="56888" txt_i="21575" txt_f="21595">−4.09 (−6.23, −1.94)</offsets></td><td char="." id="dom12779-ent-0199" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="56979" xml_f="56987" txt_i="21596" txt_f="21601">&lt;.001</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0200" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="57103" xml_f="57154" txt_i="21602" txt_f="21653">Total lean tissue, adjusted mean change (95% CI), l</offsets></td><td char="(" id="dom12779-ent-0201" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="57245" xml_f="57265" txt_i="21654" txt_f="21674">−0.91 (−1.45, −0.37)</offsets></td><td char="(" id="dom12779-ent-0202" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="57356" xml_f="57376" txt_i="21675" txt_f="21695">−0.72 (−1.30, −0.14)</offsets></td><td char="(" id="dom12779-ent-0203" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="57467" xml_f="57486" txt_i="21696" txt_f="21715">−0.19 (−0.94, 0.56)</offsets></td><td char="." id="dom12779-ent-0204" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="57577" xml_f="57581" txt_i="21716" txt_f="21720">.614</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0205" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="57697" xml_f="57751" txt_i="21721" txt_f="21775">Liver fat, adjusted mean percentage change (95% CI), %</offsets></td><td char="(" id="dom12779-ent-0206" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="57842" xml_f="57862" txt_i="21776" txt_f="21796">−1.41 (−2.75, −0.08)</offsets></td><td char="(" id="dom12779-ent-0207" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="57953" xml_f="57972" txt_i="21797" txt_f="21816">−0.31 (−1.71, 1.08)</offsets></td><td char="(" id="dom12779-ent-0208" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="58063" xml_f="58082" txt_i="21817" txt_f="21836">−1.10 (−3.01, 0.82)</offsets></td><td char="." id="dom12779-ent-0209" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="58173" xml_f="58177" txt_i="21837" txt_f="21841">.254</offsets></td></tr><tr><td colspan="5" style="padding-left:10%" id="dom12779-ent-0210" align="left" valign="top" rowspan="1"><offsets xml_i="58293" xml_f="58311" txt_i="21842" txt_f="21860">Glycaemic measures</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0211" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="58427" xml_f="58464" txt_i="21861" txt_f="21898">HbA1c, adjusted mean change (95% CI),</offsets><xref ref-type="fn" rid="dom12779-note-0015"><offsets xml_i="58509" xml_f="58510" txt_i="21898" txt_f="21899">a</offsets></xref><offsets xml_i="58517" xml_f="58526" txt_i="21899" txt_f="21908"> mmol/mol</offsets></td><td char="(" id="dom12779-ent-0212" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="58617" xml_f="58634" txt_i="21909" txt_f="21926">−3.9 (−4.7, −3.1)</offsets></td><td char="(" id="dom12779-ent-0213" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="58725" xml_f="58742" txt_i="21927" txt_f="21944">−1.6 (−2.5, −0.7)</offsets></td><td char="(" id="dom12779-ent-0214" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="58833" xml_f="58850" txt_i="21945" txt_f="21962">−2.3 (−3.5, −1.1)</offsets></td><td char="." id="dom12779-ent-0215" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="58941" xml_f="58949" txt_i="21963" txt_f="21968">&lt;.001</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0216" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="59065" xml_f="59102" txt_i="21969" txt_f="22006">HbA1c, adjusted mean change (95% CI),</offsets><xref ref-type="fn" rid="dom12779-note-0015"><offsets xml_i="59147" xml_f="59148" txt_i="22006" txt_f="22007">a</offsets></xref><offsets xml_i="59155" xml_f="59157" txt_i="22007" txt_f="22009"> %</offsets></td><td char="(" id="dom12779-ent-0217" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="59248" xml_f="59268" txt_i="22010" txt_f="22030">−0.36 (−0.43, −0.28)</offsets></td><td char="(" id="dom12779-ent-0218" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="59359" xml_f="59379" txt_i="22031" txt_f="22051">−0.15 (−0.23, −0.06)</offsets></td><td char="(" id="dom12779-ent-0219" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="59470" xml_f="59490" txt_i="22052" txt_f="22072">−0.21 (−0.32, −0.10)</offsets></td><td char="." id="dom12779-ent-0220" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="59581" xml_f="59589" txt_i="22073" txt_f="22078">&lt;.001</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0221" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="59705" xml_f="59740" txt_i="22079" txt_f="22114">FPG, adjusted mean change (95% CI),</offsets><xref ref-type="fn" rid="dom12779-note-0016"><offsets xml_i="59785" xml_f="59786" txt_i="22114" txt_f="22115">b</offsets></xref><offsets xml_i="59793" xml_f="59800" txt_i="22115" txt_f="22122"> mmol/l</offsets></td><td char="(" id="dom12779-ent-0222" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="59891" xml_f="59911" txt_i="22123" txt_f="22143">−0.41 (−0.61, −0.22)</offsets></td><td char="(" id="dom12779-ent-0223" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="60002" xml_f="60019" txt_i="22144" txt_f="22161">0.25 (0.05, 0.46)</offsets></td><td char="(" id="dom12779-ent-0224" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="60110" xml_f="60130" txt_i="22162" txt_f="22182">−0.66 (−0.94, −0.39)</offsets></td><td char="." id="dom12779-ent-0225" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="60221" xml_f="60229" txt_i="22183" txt_f="22188">&lt;.001</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0226" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="60345" xml_f="60383" txt_i="22189" txt_f="22227">2‐h PG, adjusted mean change (95% CI),</offsets><xref ref-type="fn" rid="dom12779-note-0016"><offsets xml_i="60428" xml_f="60429" txt_i="22227" txt_f="22228">b</offsets></xref><offsets xml_i="60436" xml_f="60443" txt_i="22228" txt_f="22235"> mmol/L</offsets></td><td char="(" id="dom12779-ent-0227" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="60534" xml_f="60554" txt_i="22236" txt_f="22256">−1.57 (−2.36, −0.78)</offsets></td><td char="(" id="dom12779-ent-0228" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="60645" xml_f="60664" txt_i="22257" txt_f="22276">−0.08 (−0.93, 0.76)</offsets></td><td char="(" id="dom12779-ent-0229" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="60755" xml_f="60775" txt_i="22277" txt_f="22297">−1.49 (−2.65, −0.33)</offsets></td><td char="." id="dom12779-ent-0230" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="60866" xml_f="60870" txt_i="22298" txt_f="22302">.013</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0231" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="60986" xml_f="61014" txt_i="22303" txt_f="22331">Proportion with IFG, n/N (%)</offsets></td><td char="(" id="dom12779-ent-0232" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="61105" xml_f="61116" txt_i="22332" txt_f="22343">8/23 (34.8)</offsets></td><td char="(" id="dom12779-ent-0233" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="61207" xml_f="61219" txt_i="22344" txt_f="22356">17/20 (85.0)</offsets></td><td id="dom12779-ent-0234" align="char" valign="top" rowspan="1" colspan="1"></td><td char="." id="dom12779-ent-0235" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="61392" xml_f="61400" txt_i="22358" txt_f="22363">&lt;.001</offsets><xref ref-type="fn" rid="dom12779-note-0018"><offsets xml_i="61445" xml_f="61446" txt_i="22363" txt_f="22364">d</offsets></xref><offsets xml_i="61453" xml_f="61454" txt_i="22364" txt_f="22365">
</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0236" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="61570" xml_f="61598" txt_i="22366" txt_f="22394">Proportion with IGT, n/N (%)</offsets></td><td char="(" id="dom12779-ent-0237" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="61689" xml_f="61700" txt_i="22395" txt_f="22406">4/23 (17.4)</offsets></td><td char="(" id="dom12779-ent-0238" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="61791" xml_f="61802" txt_i="22407" txt_f="22418">8/20 (40.0)</offsets></td><td id="dom12779-ent-0239" align="char" valign="top" rowspan="1" colspan="1"></td><td char="." id="dom12779-ent-0240" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="61975" xml_f="61979" txt_i="22420" txt_f="22424">.066</offsets><xref ref-type="fn" rid="dom12779-note-0018"><offsets xml_i="62024" xml_f="62025" txt_i="22424" txt_f="22425">d</offsets></xref><offsets xml_i="62032" xml_f="62033" txt_i="22425" txt_f="22426">
</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0241" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="62149" xml_f="62202" txt_i="22427" txt_f="22480">Proportion with any IFG or IGT (prediabetes), n/N (%)</offsets></td><td char="(" id="dom12779-ent-0242" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="62293" xml_f="62304" txt_i="22481" txt_f="22492">8/23 (34.8)</offsets></td><td char="(" id="dom12779-ent-0243" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="62395" xml_f="62407" txt_i="22493" txt_f="22505">17/20 (85.0)</offsets></td><td id="dom12779-ent-0244" align="char" valign="top" rowspan="1" colspan="1"></td><td char="." id="dom12779-ent-0245" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="62580" xml_f="62584" txt_i="22507" txt_f="22511">.002</offsets><xref ref-type="fn" rid="dom12779-note-0018"><offsets xml_i="62629" xml_f="62630" txt_i="22511" txt_f="22512">d</offsets></xref><offsets xml_i="62637" xml_f="62638" txt_i="22512" txt_f="22513">
</offsets></td></tr><tr><td colspan="5" style="padding-left:10%" id="dom12779-ent-0246" align="left" valign="top" rowspan="1"><offsets xml_i="62754" xml_f="62765" txt_i="22514" txt_f="22525">Vital signs</offsets><xref ref-type="fn" rid="dom12779-note-0015"><offsets xml_i="62810" xml_f="62811" txt_i="22525" txt_f="22526">a</offsets></xref><offsets xml_i="62818" xml_f="62819" txt_i="22526" txt_f="22527">
</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0247" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="62935" xml_f="62976" txt_i="22528" txt_f="22569">DBP, adjusted mean change (95% CI), mm Hg</offsets></td><td char="(" id="dom12779-ent-0248" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="63067" xml_f="63082" txt_i="22570" txt_f="22585">1.8 (−2.7, 6.3)</offsets></td><td char="(" id="dom12779-ent-0249" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="63173" xml_f="63188" txt_i="22586" txt_f="22601">2.3 (−2.6, 7.1)</offsets></td><td char="(" id="dom12779-ent-0250" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="63279" xml_f="63295" txt_i="22602" txt_f="22618">−0.5 (−7.1, 6.1)</offsets></td><td char="." id="dom12779-ent-0251" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="63386" xml_f="63390" txt_i="22619" txt_f="22623">.883</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0252" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="63506" xml_f="63547" txt_i="22624" txt_f="22665">SBP, adjusted mean change (95% CI), mm Hg</offsets></td><td char="(" id="dom12779-ent-0253" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="63638" xml_f="63656" txt_i="22666" txt_f="22684">−9.6 (−13.6, −5.7)</offsets></td><td char="(" id="dom12779-ent-0254" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="63747" xml_f="63763" txt_i="22685" txt_f="22701">−3.0 (−7.1, 1.2)</offsets></td><td char="(" id="dom12779-ent-0255" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="63854" xml_f="63872" txt_i="22702" txt_f="22720">−6.7 (−12.4, −1.0)</offsets></td><td char="." id="dom12779-ent-0256" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="63963" xml_f="63967" txt_i="22721" txt_f="22725">.022</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0257" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="64083" xml_f="64129" txt_i="22726" txt_f="22772">Heart rate, adjusted mean change (95% CI), bpm</offsets></td><td char="(" id="dom12779-ent-0258" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="64220" xml_f="64235" txt_i="22773" txt_f="22788">2.6 (−0.1, 5.3)</offsets></td><td char="(" id="dom12779-ent-0259" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="64326" xml_f="64341" txt_i="22789" txt_f="22804">0.4 (−2.5, 3.3)</offsets></td><td char="(" id="dom12779-ent-0260" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="64432" xml_f="64447" txt_i="22805" txt_f="22820">2.1 (−1.8, 6.1)</offsets></td><td char="." id="dom12779-ent-0261" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="64538" xml_f="64542" txt_i="22821" txt_f="22825">.281</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0262" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="64658" xml_f="64709" txt_i="22826" txt_f="22877">Waist circumference, adjusted mean change (95% CI),</offsets><xref ref-type="fn" rid="dom12779-note-0015"><offsets xml_i="64754" xml_f="64755" txt_i="22877" txt_f="22878">a</offsets></xref><offsets xml_i="64762" xml_f="64765" txt_i="22878" txt_f="22881"> cm</offsets></td><td char="(" id="dom12779-ent-0263" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="64856" xml_f="64873" txt_i="22882" txt_f="22899">−5.3 (−7.5, −3.1)</offsets></td><td char="(" id="dom12779-ent-0264" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="64964" xml_f="64981" txt_i="22900" txt_f="22917">−2.6 (−4.8, −0.3)</offsets></td><td char="(" id="dom12779-ent-0265" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="65072" xml_f="65088" txt_i="22918" txt_f="22934">−2.8 (−5.9, 0.4)</offsets></td><td char="." id="dom12779-ent-0266" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="65179" xml_f="65183" txt_i="22935" txt_f="22939">.083</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0267" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="65299" xml_f="65348" txt_i="22940" txt_f="22989">Waist‐to‐hip ratio, adjusted mean change (95% CI)</offsets><xref ref-type="fn" rid="dom12779-note-0015"><offsets xml_i="65393" xml_f="65394" txt_i="22989" txt_f="22990">a</offsets></xref><offsets xml_i="65401" xml_f="65402" txt_i="22990" txt_f="22991">
</offsets></td><td char="(" id="dom12779-ent-0268" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="65493" xml_f="65513" txt_i="22992" txt_f="23012">−0.02 (−0.04, 0.000)</offsets></td><td char="(" id="dom12779-ent-0269" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="65604" xml_f="65623" txt_i="23013" txt_f="23032">−0.01 (−0.03, 0.01)</offsets></td><td char="(" id="dom12779-ent-0270" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="65714" xml_f="65733" txt_i="23033" txt_f="23052">−0.01 (−0.03, 0.02)</offsets></td><td char="." id="dom12779-ent-0271" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="65824" xml_f="65828" txt_i="23053" txt_f="23057">.710</offsets></td></tr><tr><td colspan="5" char="." id="dom12779-ent-0272" align="left" valign="top" rowspan="1"><offsets xml_i="65928" xml_f="65953" txt_i="23058" txt_f="23083">Urinary glucose excretion</offsets><xref ref-type="fn" rid="dom12779-note-0019"><offsets xml_i="65998" xml_f="65999" txt_i="23083" txt_f="23084">e</offsets></xref><offsets xml_i="66006" xml_f="66007" txt_i="23084" txt_f="23085">
</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0273" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="66123" xml_f="66144" txt_i="23086" txt_f="23107">Mean (s.d.), mmol/3 h</offsets></td><td char="(" id="dom12779-ent-0274" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="66235" xml_f="66246" txt_i="23108" txt_f="23119">50.5 (31.4)</offsets></td><td char="(" id="dom12779-ent-0275" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="66337" xml_f="66347" txt_i="23120" txt_f="23130">0.26 (0.8)</offsets></td><td id="dom12779-ent-0276" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0277" align="char" valign="top" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="dom12779-note-0013"><p><offsets xml_i="66585" xml_f="66599" txt_i="23133" txt_f="23147">Abbreviation: </offsets><styled-content style="fixed-case"><offsets xml_i="66634" xml_f="66636" txt_i="23147" txt_f="23149">PG</offsets></styled-content><offsets xml_i="66653" xml_f="66670" txt_i="23149" txt_f="23166">, plasma glucose.</offsets></p></fn><fn id="dom12779-note-0014"><p><offsets xml_i="66710" xml_f="66711" txt_i="23167" txt_f="23168">
</offsets><styled-content style="fixed-case"><offsets xml_i="66746" xml_f="66749" txt_i="23168" txt_f="23171">IFG</offsets></styled-content><offsets xml_i="66766" xml_f="66781" txt_i="23171" txt_f="23186"> defined as an </offsets><styled-content style="fixed-case"><offsets xml_i="66816" xml_f="66819" txt_i="23186" txt_f="23189">FPG</offsets></styled-content><offsets xml_i="66836" xml_f="66873" txt_i="23189" txt_f="23226"> ≥5.6 mmol/L measured just before an </offsets><styled-content style="fixed-case"><offsets xml_i="66908" xml_f="66912" txt_i="23226" txt_f="23230">OGTT</offsets></styled-content><offsets xml_i="66929" xml_f="66953" txt_i="23230" txt_f="23254"> at the 24‐week visit). </offsets><styled-content style="fixed-case"><offsets xml_i="66988" xml_f="66991" txt_i="23254" txt_f="23257">IGT</offsets></styled-content><offsets xml_i="67008" xml_f="67094" txt_i="23257" txt_f="23343"> defined as a plasma glucose value ≥7.8 mmol/L measured 2 hours after the start of an </offsets><styled-content style="fixed-case"><offsets xml_i="67129" xml_f="67133" txt_i="23343" txt_f="23347">OGTT</offsets></styled-content><offsets xml_i="67150" xml_f="67180" txt_i="23347" txt_f="23377"> at the 24‐week visit; 2‐hour </offsets><styled-content style="fixed-case"><offsets xml_i="67215" xml_f="67217" txt_i="23377" txt_f="23379">PG</offsets></styled-content><offsets xml_i="67234" xml_f="67276" txt_i="23379" txt_f="23421">, measured 2 hours after the start of the </offsets><styled-content style="fixed-case"><offsets xml_i="67311" xml_f="67315" txt_i="23421" txt_f="23425">OGTT</offsets></styled-content><offsets xml_i="67332" xml_f="67333" txt_i="23425" txt_f="23426">.</offsets></p></fn><fn id="dom12779-note-0015"><label><offsets xml_i="67377" xml_f="67378" txt_i="23427" txt_f="23428">a</offsets></label><p><offsets xml_i="67389" xml_f="67398" txt_i="23428" txt_f="23437">Data are </offsets><styled-content style="fixed-case"><offsets xml_i="67433" xml_f="67435" txt_i="23437" txt_f="23439">LS</offsets></styled-content><offsets xml_i="67452" xml_f="67500" txt_i="23439" txt_f="23487"> mean changes from baseline to 24 weeks and 95% </offsets><styled-content style="fixed-case"><offsets xml_i="67535" xml_f="67537" txt_i="23487" txt_f="23489">CI</offsets></styled-content><offsets xml_i="67554" xml_f="67678" txt_i="23489" txt_f="23613">s derived from a mixed model for repeated measures adjusted for treatment, week, treatment‐by‐week, sex, and baseline value.</offsets></p></fn><fn id="dom12779-note-0016"><label><offsets xml_i="67722" xml_f="67723" txt_i="23614" txt_f="23615">b</offsets></label><p><offsets xml_i="67734" xml_f="67743" txt_i="23615" txt_f="23624">Data are </offsets><styled-content style="fixed-case"><offsets xml_i="67778" xml_f="67780" txt_i="23624" txt_f="23626">LS</offsets></styled-content><offsets xml_i="67797" xml_f="67845" txt_i="23626" txt_f="23674"> mean changes from baseline to 24 weeks and 95% </offsets><styled-content style="fixed-case"><offsets xml_i="67880" xml_f="67882" txt_i="23674" txt_f="23676">CI</offsets></styled-content><offsets xml_i="67899" xml_f="67994" txt_i="23676" txt_f="23771">s derived from an analysis of covariance model adjusted for treatment, sex, and baseline value.</offsets></p></fn><fn id="dom12779-note-0017"><label><offsets xml_i="68038" xml_f="68039" txt_i="23772" txt_f="23773">c</offsets></label><p><offsets xml_i="68050" xml_f="68153" txt_i="23773" txt_f="23876">Defined as the subcutaneous fat positioned between the hip joint and up to the lower pole of the lungs.</offsets></p></fn><fn id="dom12779-note-0018"><label><offsets xml_i="68197" xml_f="68198" txt_i="23877" txt_f="23878">d</offsets></label><p><offsets xml_i="68209" xml_f="68280" txt_i="23878" txt_f="23949">p value based on a Cochran–Mantel–Haenszel test adjusted for treatment.</offsets></p></fn><fn id="dom12779-note-0019"><label><offsets xml_i="68324" xml_f="68325" txt_i="23950" txt_f="23951">e</offsets></label><p><offsets xml_i="68336" xml_f="68400" txt_i="23951" txt_f="24015">Values at 24 weeks derived from urine collected during a 3‐hour </offsets><styled-content style="fixed-case"><offsets xml_i="68435" xml_f="68439" txt_i="24015" txt_f="24019">OGTT</offsets></styled-content><offsets xml_i="68456" xml_f="68457" txt_i="24019" txt_f="24020">.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="dom12779-sec-0018"><label><offsets xml_i="68538" xml_f="68543" txt_i="24022" txt_f="24027">3.2.2</offsets></label><title><offsets xml_i="68558" xml_f="68559" txt_i="24027" txt_f="24028">
</offsets><styled-content style="fixed-case"><offsets xml_i="68594" xml_f="68597" txt_i="24028" txt_f="24031">MRI</offsets></styled-content><offsets xml_i="68614" xml_f="68634" txt_i="24031" txt_f="24051"> of body composition</offsets></title><p id="dom12779-para-0032"><offsets xml_i="68669" xml_f="68891" txt_i="24052" txt_f="24274">Dapagliflozin/exenatide reduced visceral, subcutaneous and total adipose tissue volume, but not lean tissue, significantly more than placebo. Total adipose tissue reduction versus placebo was −4.09 L after 24 weeks (Table </offsets><xref rid="dom12779-tbl-0002" ref-type="table-wrap"><offsets xml_i="68943" xml_f="68944" txt_i="24274" txt_f="24275">2</offsets></xref><offsets xml_i="68951" xml_f="69109" txt_i="24275" txt_f="24433">). Although dapagliflozin/exenatide significantly reduced percent liver fat from baseline, this reduction was not significantly different from placebo (Table </offsets><xref rid="dom12779-tbl-0002" ref-type="table-wrap"><offsets xml_i="69161" xml_f="69162" txt_i="24433" txt_f="24434">2</offsets></xref><offsets xml_i="69169" xml_f="69171" txt_i="24434" txt_f="24436">).</offsets></p></sec><sec id="dom12779-sec-0019"><label><offsets xml_i="69216" xml_f="69221" txt_i="24438" txt_f="24443">3.2.3</offsets></label><title><offsets xml_i="69236" xml_f="69255" txt_i="24443" txt_f="24462">Glycaemic variables</offsets></title><p id="dom12779-para-0033"><offsets xml_i="69290" xml_f="69412" txt_i="24463" txt_f="24585">Dapagliflozin/exenatide reduced HbA1c, FPG and 2‐hour plasma glucose significantly more than placebo over 24 weeks (Table </offsets><xref rid="dom12779-tbl-0002" ref-type="table-wrap"><offsets xml_i="69464" xml_f="69465" txt_i="24585" txt_f="24586">2</offsets></xref><offsets xml_i="69472" xml_f="69481" txt_i="24586" txt_f="24595">; Figure </offsets><xref rid="dom12779-fig-0002" ref-type="fig"><offsets xml_i="69526" xml_f="69527" txt_i="24595" txt_f="24596">2</offsets></xref><offsets xml_i="69534" xml_f="69626" txt_i="24596" txt_f="24688">E,F), with mean differences of −2.3 mmol/mol (−0.21%), −0.66 and −1.49 mmol/L, respectively.</offsets></p><p id="dom12779-para-0034"><offsets xml_i="69657" xml_f="70385" txt_i="24689" txt_f="25417">Although the participants did not have diabetes, OGTTs showed that many had abnormal glucose metabolism at baseline, which improved with dapagliflozin/exenatide but not placebo. The proportion of dapagliflozin/exenatide‐treated participants with IFG was significantly reduced, from 64.0% at baseline to 34.8% at week 24 (p = .008), and with IGT was significantly reduced from 48.0% to 17.4% (p = .020). Combined, the proportion of participants with prediabetes (any IFG or IGT) significantly decreased from 68.0% to 34.8% (p = .005). In contrast, the corresponding proportions among placebo‐treated participants did not change significantly from baseline to 24 weeks (70.8%–85.0%, 33.3%–40.0% and 79.2%–85.0%, respectively; all </offsets><italic><offsets xml_i="70393" xml_f="70394" txt_i="25417" txt_f="25418">P</offsets></italic><offsets xml_i="70403" xml_f="70420" txt_i="25418" txt_f="25432"> &gt; .3; Figure </offsets><xref rid="dom12779-fig-0002" ref-type="fig"><offsets xml_i="70465" xml_f="70466" txt_i="25432" txt_f="25433">2</offsets></xref><offsets xml_i="70473" xml_f="70624" txt_i="25433" txt_f="25584">G). Reduction in prediabetes (any IFG or IGT) from baseline to 24 weeks was significantly greater with dapagliflozin/exenatide than placebo (p = .002).</offsets></p><p id="dom12779-para-0035"><offsets xml_i="70655" xml_f="70846" txt_i="25585" txt_f="25776">No participants had overt glucosuria at baseline. After 24 weeks, mean urinary glucose was substantially greater with dapagliflozin/exenatide (50.5 mmol/3 h) than with placebo (0.3 mmol/3 h).</offsets></p></sec><sec id="dom12779-sec-0020"><label><offsets xml_i="70891" xml_f="70896" txt_i="25778" txt_f="25783">3.2.4</offsets></label><title><offsets xml_i="70911" xml_f="70922" txt_i="25783" txt_f="25794">Vital signs</offsets></title><p id="dom12779-para-0036"><offsets xml_i="70957" xml_f="71113" txt_i="25795" txt_f="25951">In this predominantly normotensive population (mean baseline SBP of 134 mm Hg), dapagliflozin/exenatide reduced SBP significantly more than placebo (Figure </offsets><xref rid="dom12779-fig-0002" ref-type="fig"><offsets xml_i="71158" xml_f="71159" txt_i="25951" txt_f="25952">2</offsets></xref><offsets xml_i="71166" xml_f="71337" txt_i="25952" txt_f="26123">H), with a mean difference of −6.7 mm Hg after 24 weeks. No significant differences between dapagliflozin/exenatide and placebo were observed for DBP or heart rate (Table </offsets><xref rid="dom12779-tbl-0002" ref-type="table-wrap"><offsets xml_i="71389" xml_f="71390" txt_i="26123" txt_f="26124">2</offsets></xref><offsets xml_i="71397" xml_f="71831" txt_i="26124" txt_f="26558">). Some participants, mainly in the dapagliflozin/exenatide group, had pronounced reductions in SBP; however, this did not lead to withdrawal or dose reduction of antihypertensive drugs among participants treated for hypertension. Hypotension was reported in only one placebo‐treated participant. New antihypertensive therapies were started in three participants, one in the dapagliflozin/exenatide group and two in the placebo group.</offsets></p></sec></sec><sec id="dom12779-sec-0021"><label><offsets xml_i="71882" xml_f="71885" txt_i="26561" txt_f="26564">3.3</offsets></label><title><offsets xml_i="71900" xml_f="71923" txt_i="26564" txt_f="26587">Safety and tolerability</offsets></title><p id="dom12779-para-0037"><offsets xml_i="71958" xml_f="72091" txt_i="26588" txt_f="26721">No meaningful differences between dapagliflozin/exenatide and placebo were observed for eGFR, fasting ketones or serum lipids (Table </offsets><xref rid="dom12779-tbl-0003" ref-type="table-wrap"><offsets xml_i="72143" xml_f="72144" txt_i="26721" txt_f="26722">3</offsets></xref><offsets xml_i="72151" xml_f="72202" txt_i="26722" txt_f="26773">), or other safety laboratory variables (Table S1).</offsets></p><table-wrap id="dom12779-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label><offsets xml_i="72302" xml_f="72309" txt_i="26774" txt_f="26781">Table 3</offsets></label><caption><p><offsets xml_i="72329" xml_f="72377" txt_i="26781" txt_f="26829">Key laboratory changes and safety after 24 weeks</offsets></p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"></col><col width="1*" align="char" char="(" span="1"></col><col width="1*" align="char" char="(" span="1"></col><col width="1*" align="char" char="(" span="1"></col><col width="1*" align="char" char="(" span="1"></col><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="dom12779-ent-0278" align="left" valign="bottom" rowspan="1" colspan="1"></th><th id="dom12779-ent-0279" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="72916" xml_f="72917" txt_i="26830" txt_f="26831">
</offsets><bold><offsets xml_i="72923" xml_f="72982" txt_i="26831" txt_f="26890">Dapagliflozin 10 mg once daily + exenatide 2 mg once weekly</offsets></bold><offsets xml_i="72989" xml_f="72990" txt_i="26890" txt_f="26891">
</offsets></th><th id="dom12779-ent-0280" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="73075" xml_f="73076" txt_i="26891" txt_f="26892">
</offsets><bold><offsets xml_i="73082" xml_f="73144" txt_i="26892" txt_f="26954">Placebo oral tablet once daily + placebo injection once weekly</offsets></bold><offsets xml_i="73151" xml_f="73152" txt_i="26954" txt_f="26955">
</offsets></th><th id="dom12779-ent-0281" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="73237" xml_f="73238" txt_i="26955" txt_f="26956">
</offsets><bold><offsets xml_i="73244" xml_f="73289" txt_i="26956" txt_f="27001">Dapagliflozin/exenatide vs placebo difference</offsets></bold><offsets xml_i="73296" xml_f="73297" txt_i="27001" txt_f="27002">
</offsets></th><th id="dom12779-ent-0282" align="char" valign="bottom" rowspan="1" colspan="1"><offsets xml_i="73382" xml_f="73383" txt_i="27002" txt_f="27003">
</offsets><bold><italic><offsets xml_i="73397" xml_f="73398" txt_i="27003" txt_f="27004">P</offsets></italic><offsets xml_i="73407" xml_f="73413" txt_i="27004" txt_f="27010"> value</offsets></bold><offsets xml_i="73420" xml_f="73421" txt_i="27010" txt_f="27011">
</offsets></th></tr></thead><tbody valign="top"><tr><td id="dom12779-ent-0283" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="73540" xml_f="73583" txt_i="27011" txt_f="27054">Laboratory variables analysed using the FAS</offsets></td><td id="dom12779-ent-0284" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="73665" xml_f="73671" txt_i="27055" txt_f="27061">n = 25</offsets></td><td id="dom12779-ent-0285" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="73753" xml_f="73759" txt_i="27062" txt_f="27068">n = 24</offsets></td><td id="dom12779-ent-0286" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0287" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0288" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="74039" xml_f="74044" txt_i="27071" txt_f="27076">eGFR,</offsets><xref ref-type="fn" rid="dom12779-note-0020"><offsets xml_i="74089" xml_f="74090" txt_i="27076" txt_f="27077">a</offsets></xref><offsets xml_i="74097" xml_f="74128" txt_i="27077" txt_f="27108"> adjusted mean change (95% CI),</offsets><xref ref-type="fn" rid="dom12779-note-0021"><offsets xml_i="74173" xml_f="74174" txt_i="27108" txt_f="27109">b</offsets></xref><offsets xml_i="74181" xml_f="74195" txt_i="27109" txt_f="27123"> mL/min/1.73 m</offsets><sup><offsets xml_i="74200" xml_f="74201" txt_i="27123" txt_f="27124">2</offsets></sup><offsets xml_i="74207" xml_f="74208" txt_i="27124" txt_f="27125">
</offsets></td><td char="(" id="dom12779-ent-0289" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="74299" xml_f="74318" txt_i="27126" txt_f="27145">−1.97 (−6.52, 2.59)</offsets></td><td char="(" id="dom12779-ent-0290" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="74409" xml_f="74427" txt_i="27146" txt_f="27164">2.47 (−2.65, 7.59)</offsets></td><td char="(" id="dom12779-ent-0291" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="74518" xml_f="74538" txt_i="27165" txt_f="27185">−4.44 (−11.22, 2.35)</offsets></td><td char="." id="dom12779-ent-0292" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="74629" xml_f="74633" txt_i="27186" txt_f="27190">.193</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0293" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="74749" xml_f="74796" txt_i="27191" txt_f="27238">Fasting ketones, adjusted mean change (95% CI),</offsets><xref ref-type="fn" rid="dom12779-note-0022"><offsets xml_i="74841" xml_f="74842" txt_i="27238" txt_f="27239">c</offsets></xref><offsets xml_i="74849" xml_f="74856" txt_i="27239" txt_f="27246"> mmol/L</offsets></td><td char="(" id="dom12779-ent-0294" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="74947" xml_f="74965" txt_i="27247" txt_f="27265">0.01 (−0.03, 0.06)</offsets></td><td char="(" id="dom12779-ent-0295" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="75056" xml_f="75075" txt_i="27266" txt_f="27285">−0.03 (−0.08, 0.01)</offsets></td><td char="(" id="dom12779-ent-0296" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="75166" xml_f="75184" txt_i="27286" txt_f="27304">0.05 (−0.02, 0.11)</offsets></td><td char="." id="dom12779-ent-0297" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="75275" xml_f="75279" txt_i="27305" txt_f="27309">.149</offsets></td></tr><tr><td colspan="5" style="padding-left:10%" id="dom12779-ent-0298" align="left" valign="top" rowspan="1"><offsets xml_i="75395" xml_f="75438" txt_i="27310" txt_f="27353">Serum lipids, adjusted mean change (95% CI)</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0299" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="75554" xml_f="75572" txt_i="27354" txt_f="27372">Total cholesterol,</offsets><xref ref-type="fn" rid="dom12779-note-0021"><offsets xml_i="75617" xml_f="75618" txt_i="27372" txt_f="27373">b</offsets></xref><offsets xml_i="75625" xml_f="75632" txt_i="27373" txt_f="27380"> mmol/L</offsets></td><td char="(" id="dom12779-ent-0300" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="75723" xml_f="75742" txt_i="27381" txt_f="27400">−0.17 (−0.42, 0.09)</offsets></td><td char="(" id="dom12779-ent-0301" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="75833" xml_f="75852" txt_i="27401" txt_f="27420">−0.26 (−0.54, 0.01)</offsets></td><td char="(" id="dom12779-ent-0302" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="75943" xml_f="75961" txt_i="27421" txt_f="27439">0.10 (−0.27, 0.47)</offsets></td><td char="." id="dom12779-ent-0303" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="76052" xml_f="76056" txt_i="27440" txt_f="27444">.596</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0304" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="76172" xml_f="76188" txt_i="27445" txt_f="27461">LDL cholesterol,</offsets><xref ref-type="fn" rid="dom12779-note-0021"><offsets xml_i="76233" xml_f="76234" txt_i="27461" txt_f="27462">b</offsets></xref><offsets xml_i="76241" xml_f="76248" txt_i="27462" txt_f="27469"> mmol/L</offsets></td><td char="(" id="dom12779-ent-0305" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="76339" xml_f="76358" txt_i="27470" txt_f="27489">−0.17 (−0.38, 0.04)</offsets></td><td char="(" id="dom12779-ent-0306" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="76449" xml_f="76469" txt_i="27490" txt_f="27510">−0.22 (−0.44, −0.00)</offsets></td><td char="(" id="dom12779-ent-0307" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="76560" xml_f="76578" txt_i="27511" txt_f="27529">0.05 (−0.25, 0.35)</offsets></td><td char="." id="dom12779-ent-0308" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="76669" xml_f="76673" txt_i="27530" txt_f="27534">.727</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0309" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="76789" xml_f="76805" txt_i="27535" txt_f="27551">HDL cholesterol,</offsets><xref ref-type="fn" rid="dom12779-note-0021"><offsets xml_i="76850" xml_f="76851" txt_i="27551" txt_f="27552">b</offsets></xref><offsets xml_i="76858" xml_f="76865" txt_i="27552" txt_f="27559"> mmol/L</offsets></td><td char="(" id="dom12779-ent-0310" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="76956" xml_f="76974" txt_i="27560" txt_f="27578">0.02 (−0.06, 0.09)</offsets></td><td char="(" id="dom12779-ent-0311" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="77065" xml_f="77084" txt_i="27579" txt_f="27598">−0.07 (−0.15, 0.01)</offsets></td><td char="(" id="dom12779-ent-0312" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="77175" xml_f="77193" txt_i="27599" txt_f="27617">0.09 (−0.02, 0.20)</offsets></td><td char="." id="dom12779-ent-0313" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="77284" xml_f="77288" txt_i="27618" txt_f="27622">.101</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0314" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="77404" xml_f="77417" txt_i="27623" txt_f="27636">Triglycerides</offsets><xref ref-type="fn" rid="dom12779-note-0021"><offsets xml_i="77462" xml_f="77463" txt_i="27636" txt_f="27637">b</offsets></xref><offsets xml_i="77470" xml_f="77477" txt_i="27637" txt_f="27644"> mmol/L</offsets></td><td char="(" id="dom12779-ent-0315" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="77568" xml_f="77587" txt_i="27645" txt_f="27664">−0.10 (−0.29, 0.10)</offsets></td><td char="(" id="dom12779-ent-0316" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="77678" xml_f="77697" txt_i="27665" txt_f="27684">−0.01 (−0.21, 0.20)</offsets></td><td char="(" id="dom12779-ent-0317" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="77788" xml_f="77807" txt_i="27685" txt_f="27704">−0.09 (−0.37, 0.19)</offsets></td><td char="." id="dom12779-ent-0318" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="77898" xml_f="77902" txt_i="27705" txt_f="27709">.516</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0319" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="78018" xml_f="78035" txt_i="27710" txt_f="27727">Free fatty acids,</offsets><xref ref-type="fn" rid="dom12779-note-0022"><offsets xml_i="78080" xml_f="78081" txt_i="27727" txt_f="27728">c</offsets></xref><offsets xml_i="78088" xml_f="78095" txt_i="27728" txt_f="27735"> µmol/L</offsets></td><td char="(" id="dom12779-ent-0320" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="78186" xml_f="78204" txt_i="27736" txt_f="27754">−0.8 (−19.9, 18.3)</offsets></td><td char="(" id="dom12779-ent-0321" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="78295" xml_f="78313" txt_i="27755" txt_f="27773">−13.5 (−34.2, 7.1)</offsets></td><td char="(" id="dom12779-ent-0322" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="78404" xml_f="78422" txt_i="27774" txt_f="27792">12.8 (−15.2, 40.7)</offsets></td><td char="." id="dom12779-ent-0323" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="78513" xml_f="78517" txt_i="27793" txt_f="27797">.361</offsets></td></tr><tr><td id="dom12779-ent-0324" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="78608" xml_f="78663" txt_i="27798" txt_f="27853">Safety variables analysed using the safety analysis set</offsets></td><td char="(" id="dom12779-ent-0325" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="78754" xml_f="78760" txt_i="27854" txt_f="27860">n = 25</offsets></td><td char="(" id="dom12779-ent-0326" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="78851" xml_f="78857" txt_i="27861" txt_f="27867">n = 25</offsets></td><td id="dom12779-ent-0327" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0328" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" char="(" id="dom12779-ent-0329" align="left" valign="top" rowspan="1"><offsets xml_i="79121" xml_f="79161" txt_i="27870" txt_f="27910">Participants with at least one AE, n (%)</offsets></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0330" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="79277" xml_f="79283" txt_i="27911" txt_f="27917">Any AE</offsets></td><td char="(" id="dom12779-ent-0331" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="79374" xml_f="79384" txt_i="27918" txt_f="27928">25 (100.0)</offsets></td><td char="(" id="dom12779-ent-0332" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="79475" xml_f="79485" txt_i="27929" txt_f="27939">25 (100.0)</offsets></td><td id="dom12779-ent-0333" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0334" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0335" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="79765" xml_f="79780" txt_i="27942" txt_f="27957">Any serious AEs</offsets></td><td char="(" id="dom12779-ent-0336" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="79871" xml_f="79878" txt_i="27958" txt_f="27965">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0337" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="79969" xml_f="79976" txt_i="27966" txt_f="27973">1 (4.0)</offsets></td><td id="dom12779-ent-0338" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0339" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0340" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="80256" xml_f="80277" txt_i="27976" txt_f="27997">Treatment‐related AEs</offsets></td><td char="(" id="dom12779-ent-0341" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="80368" xml_f="80376" txt_i="27998" txt_f="28006">4 (16.0)</offsets></td><td char="(" id="dom12779-ent-0342" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="80467" xml_f="80475" txt_i="28007" txt_f="28015">3 (12.0)</offsets></td><td id="dom12779-ent-0343" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0344" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0345" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="80755" xml_f="80791" txt_i="28018" txt_f="28054">AEs leading to study discontinuation</offsets></td><td char="(" id="dom12779-ent-0346" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="80882" xml_f="80889" txt_i="28055" txt_f="28062">2 (8.0)</offsets></td><td char="(" id="dom12779-ent-0347" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="80980" xml_f="80988" txt_i="28063" txt_f="28071">3 (12.0)</offsets></td><td id="dom12779-ent-0348" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0349" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0350" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="81268" xml_f="81274" txt_i="28074" txt_f="28080">Deaths</offsets></td><td char="(" id="dom12779-ent-0351" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="81365" xml_f="81372" txt_i="28081" txt_f="28088">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0352" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="81463" xml_f="81470" txt_i="28089" txt_f="28096">0 (0.0)</offsets></td><td id="dom12779-ent-0353" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0354" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="padding-left:10%" id="dom12779-ent-0355" align="left" valign="top" rowspan="1"><offsets xml_i="81750" xml_f="81773" txt_i="28099" txt_f="28122">AEs of special interest</offsets><xref ref-type="fn" rid="dom12779-note-0023"><offsets xml_i="81818" xml_f="81819" txt_i="28122" txt_f="28123">d</offsets></xref><offsets xml_i="81826" xml_f="81827" txt_i="28123" txt_f="28124">
</offsets></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0356" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="81943" xml_f="81967" txt_i="28125" txt_f="28149">Urinary tract infections</offsets></td><td char="(" id="dom12779-ent-0357" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="82058" xml_f="82065" txt_i="28150" txt_f="28157">2 (8.0)</offsets></td><td char="(" id="dom12779-ent-0358" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="82156" xml_f="82163" txt_i="28158" txt_f="28165">1 (4.0)</offsets></td><td id="dom12779-ent-0359" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0360" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0361" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="82443" xml_f="82463" txt_i="28168" txt_f="28188">Acute pyelonephritis</offsets></td><td char="(" id="dom12779-ent-0362" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="82554" xml_f="82561" txt_i="28189" txt_f="28196">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0363" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="82652" xml_f="82659" txt_i="28197" txt_f="28204">0 (0.0)</offsets></td><td id="dom12779-ent-0364" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0365" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0366" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="82939" xml_f="82962" txt_i="28207" txt_f="28230">Urinary tract infection</offsets></td><td char="(" id="dom12779-ent-0367" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="83053" xml_f="83060" txt_i="28231" txt_f="28238">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0368" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="83151" xml_f="83158" txt_i="28239" txt_f="28246">1 (4.0)</offsets></td><td id="dom12779-ent-0369" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0370" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0371" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="83438" xml_f="83468" txt_i="28249" txt_f="28279">Fungal urinary tract infection</offsets></td><td char="(" id="dom12779-ent-0372" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="83559" xml_f="83566" txt_i="28280" txt_f="28287">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0373" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="83657" xml_f="83664" txt_i="28288" txt_f="28295">0 (0.0)</offsets></td><td id="dom12779-ent-0374" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0375" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0376" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="83944" xml_f="83962" txt_i="28298" txt_f="28316">Genital infections</offsets></td><td char="(" id="dom12779-ent-0377" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="84053" xml_f="84060" txt_i="28317" txt_f="28324">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0378" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="84151" xml_f="84158" txt_i="28325" txt_f="28332">0 (0.0)</offsets></td><td id="dom12779-ent-0379" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0380" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0381" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="84438" xml_f="84455" txt_i="28335" txt_f="28352">Vaginal infection</offsets></td><td char="(" id="dom12779-ent-0382" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="84546" xml_f="84553" txt_i="28353" txt_f="28360">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0383" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="84644" xml_f="84651" txt_i="28361" txt_f="28368">0 (0.0)</offsets></td><td id="dom12779-ent-0384" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0385" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0386" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="84931" xml_f="84947" txt_i="28371" txt_f="28387">Volume reduction</offsets></td><td char="(" id="dom12779-ent-0387" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="85038" xml_f="85045" txt_i="28388" txt_f="28395">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0388" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="85136" xml_f="85143" txt_i="28396" txt_f="28403">1 (4.0)</offsets></td><td id="dom12779-ent-0389" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0390" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0391" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="85423" xml_f="85434" txt_i="28406" txt_f="28417">Hypotension</offsets></td><td char="(" id="dom12779-ent-0392" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="85525" xml_f="85532" txt_i="28418" txt_f="28425">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0393" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="85623" xml_f="85630" txt_i="28426" txt_f="28433">1 (4.0)</offsets></td><td id="dom12779-ent-0394" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0395" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0396" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="85910" xml_f="85934" txt_i="28436" txt_f="28460">Renal impairment/failure</offsets></td><td char="(" id="dom12779-ent-0397" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="86025" xml_f="86032" txt_i="28461" txt_f="28468">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0398" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="86123" xml_f="86130" txt_i="28469" txt_f="28476">0 (0.0)</offsets></td><td id="dom12779-ent-0399" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0400" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0401" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="86410" xml_f="86435" txt_i="28479" txt_f="28504">Gastrointestinal symptoms</offsets></td><td char="(" id="dom12779-ent-0402" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="86526" xml_f="86535" txt_i="28505" txt_f="28514">16 (64.0)</offsets></td><td char="(" id="dom12779-ent-0403" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="86626" xml_f="86635" txt_i="28515" txt_f="28524">10 (40.0)</offsets></td><td id="dom12779-ent-0404" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0405" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0406" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="86915" xml_f="86921" txt_i="28527" txt_f="28533">Nausea</offsets></td><td char="(" id="dom12779-ent-0407" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="87012" xml_f="87020" txt_i="28534" txt_f="28542">7 (28.0)</offsets></td><td char="(" id="dom12779-ent-0408" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="87111" xml_f="87119" txt_i="28543" txt_f="28551">3 (12.0)</offsets></td><td id="dom12779-ent-0409" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0410" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0411" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="87399" xml_f="87407" txt_i="28554" txt_f="28562">Diarrhea</offsets></td><td char="(" id="dom12779-ent-0412" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="87498" xml_f="87506" txt_i="28563" txt_f="28571">3 (12.0)</offsets></td><td char="(" id="dom12779-ent-0413" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="87597" xml_f="87605" txt_i="28572" txt_f="28580">3 (12.0)</offsets></td><td id="dom12779-ent-0414" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0415" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0416" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="87885" xml_f="87905" txt_i="28583" txt_f="28603">Abdominal distension</offsets></td><td char="(" id="dom12779-ent-0417" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="87996" xml_f="88004" txt_i="28604" txt_f="28612">3 (12.0)</offsets></td><td char="(" id="dom12779-ent-0418" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="88095" xml_f="88102" txt_i="28613" txt_f="28620">2 (8.0)</offsets></td><td id="dom12779-ent-0419" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0420" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0421" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="88382" xml_f="88390" txt_i="28623" txt_f="28631">Vomiting</offsets></td><td char="(" id="dom12779-ent-0422" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="88481" xml_f="88489" txt_i="28632" txt_f="28640">3 (12.0)</offsets></td><td char="(" id="dom12779-ent-0423" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="88580" xml_f="88587" txt_i="28641" txt_f="28648">1 (4.0)</offsets></td><td id="dom12779-ent-0424" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0425" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0426" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="88867" xml_f="88890" txt_i="28651" txt_f="28674">Gastroesophageal reflux</offsets></td><td char="(" id="dom12779-ent-0427" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="88981" xml_f="88989" txt_i="28675" txt_f="28683">3 (12.0)</offsets></td><td char="(" id="dom12779-ent-0428" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="89080" xml_f="89087" txt_i="28684" txt_f="28691">1 (4.0)</offsets></td><td id="dom12779-ent-0429" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0430" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0431" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="89367" xml_f="89379" txt_i="28694" txt_f="28706">Constipation</offsets></td><td char="(" id="dom12779-ent-0432" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="89470" xml_f="89477" txt_i="28707" txt_f="28714">2 (8.0)</offsets></td><td char="(" id="dom12779-ent-0433" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="89568" xml_f="89575" txt_i="28715" txt_f="28722">1 (4.0)</offsets></td><td id="dom12779-ent-0434" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0435" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0436" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="89855" xml_f="89864" txt_i="28725" txt_f="28734">Dyspepsia</offsets></td><td char="(" id="dom12779-ent-0437" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="89955" xml_f="89962" txt_i="28735" txt_f="28742">2 (8.0)</offsets></td><td char="(" id="dom12779-ent-0438" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="90053" xml_f="90060" txt_i="28743" txt_f="28750">0 (0.0)</offsets></td><td id="dom12779-ent-0439" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0440" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0441" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="90340" xml_f="90354" txt_i="28753" txt_f="28767">Abdominal pain</offsets></td><td char="(" id="dom12779-ent-0442" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="90445" xml_f="90452" txt_i="28768" txt_f="28775">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0443" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="90543" xml_f="90550" txt_i="28776" txt_f="28783">0 (0.0)</offsets></td><td id="dom12779-ent-0444" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0445" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0446" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="90830" xml_f="90854" txt_i="28786" txt_f="28810">Injection‐site disorders</offsets></td><td char="(" id="dom12779-ent-0447" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="90945" xml_f="90954" txt_i="28811" txt_f="28820">11 (44.0)</offsets></td><td char="(" id="dom12779-ent-0448" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="91045" xml_f="91053" txt_i="28821" txt_f="28829">8 (32.0)</offsets></td><td id="dom12779-ent-0449" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0450" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0451" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="91333" xml_f="91352" txt_i="28832" txt_f="28851">Injection‐site mass</offsets></td><td char="(" id="dom12779-ent-0452" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="91443" xml_f="91451" txt_i="28852" txt_f="28860">7 (28.0)</offsets></td><td char="(" id="dom12779-ent-0453" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="91542" xml_f="91550" txt_i="28861" txt_f="28869">5 (20.0)</offsets></td><td id="dom12779-ent-0454" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0455" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0456" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="91830" xml_f="91853" txt_i="28872" txt_f="28895">Injection‐site pruritus</offsets></td><td char="(" id="dom12779-ent-0457" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="91944" xml_f="91952" txt_i="28896" txt_f="28904">7 (28.0)</offsets></td><td char="(" id="dom12779-ent-0458" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="92043" xml_f="92050" txt_i="28905" txt_f="28912">2 (8.0)</offsets></td><td id="dom12779-ent-0459" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0460" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0461" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="92330" xml_f="92353" txt_i="28915" txt_f="28938">Injection‐site erythema</offsets></td><td char="(" id="dom12779-ent-0462" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="92444" xml_f="92452" txt_i="28939" txt_f="28947">3 (12.0)</offsets></td><td char="(" id="dom12779-ent-0463" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="92543" xml_f="92550" txt_i="28948" txt_f="28955">1 (4.0)</offsets></td><td id="dom12779-ent-0464" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0465" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0466" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="92830" xml_f="92851" txt_i="28958" txt_f="28979">Injection‐site nodule</offsets></td><td char="(" id="dom12779-ent-0467" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="92942" xml_f="92949" txt_i="28980" txt_f="28987">2 (8.0)</offsets></td><td char="(" id="dom12779-ent-0468" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="93040" xml_f="93047" txt_i="28988" txt_f="28995">1 (4.0)</offsets></td><td id="dom12779-ent-0469" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0470" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0471" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="93327" xml_f="93350" txt_i="28998" txt_f="29021">Injection‐site swelling</offsets></td><td char="(" id="dom12779-ent-0472" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="93441" xml_f="93448" txt_i="29022" txt_f="29029">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0473" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="93539" xml_f="93546" txt_i="29030" txt_f="29037">2 (8.0)</offsets></td><td id="dom12779-ent-0474" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0475" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0476" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="93826" xml_f="93845" txt_i="29040" txt_f="29059">Injection‐site pain</offsets></td><td char="(" id="dom12779-ent-0477" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="93936" xml_f="93943" txt_i="29060" txt_f="29067">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0478" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="94034" xml_f="94041" txt_i="29068" txt_f="29075">0 (0.0)</offsets></td><td id="dom12779-ent-0479" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0480" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0481" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="94321" xml_f="94340" txt_i="29078" txt_f="29097">Injection‐site cyst</offsets></td><td char="(" id="dom12779-ent-0482" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="94431" xml_f="94438" txt_i="29098" txt_f="29105">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0483" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="94529" xml_f="94536" txt_i="29106" txt_f="29113">0 (0.0)</offsets></td><td id="dom12779-ent-0484" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0485" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0486" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="94816" xml_f="94835" txt_i="29116" txt_f="29135">Injection‐site rash</offsets></td><td char="(" id="dom12779-ent-0487" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="94926" xml_f="94933" txt_i="29136" txt_f="29143">0 (0.0)</offsets></td><td char="(" id="dom12779-ent-0488" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="95024" xml_f="95031" txt_i="29144" txt_f="29151">1 (4.0)</offsets></td><td id="dom12779-ent-0489" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0490" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:10%" id="dom12779-ent-0491" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="95311" xml_f="95327" txt_i="29154" txt_f="29170">Appetite changes</offsets></td><td char="(" id="dom12779-ent-0492" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="95418" xml_f="95427" txt_i="29171" txt_f="29180">10 (40.0)</offsets></td><td char="(" id="dom12779-ent-0493" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="95518" xml_f="95526" txt_i="29181" txt_f="29189">6 (24.0)</offsets></td><td id="dom12779-ent-0494" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0495" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0496" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="95806" xml_f="95824" txt_i="29192" txt_f="29210">Decreased appetite</offsets></td><td char="(" id="dom12779-ent-0497" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="95915" xml_f="95923" txt_i="29211" txt_f="29219">8 (32.0)</offsets></td><td char="(" id="dom12779-ent-0498" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="96014" xml_f="96022" txt_i="29220" txt_f="29228">3 (12.0)</offsets></td><td id="dom12779-ent-0499" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0500" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0501" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="96302" xml_f="96320" txt_i="29231" txt_f="29249">Increased appetite</offsets></td><td char="(" id="dom12779-ent-0502" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="96411" xml_f="96418" txt_i="29250" txt_f="29257">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0503" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="96509" xml_f="96516" txt_i="29258" txt_f="29265">0 (0.0)</offsets></td><td id="dom12779-ent-0504" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0505" align="char" valign="top" rowspan="1" colspan="1"></td></tr><tr><td style="padding-left:15%" id="dom12779-ent-0506" align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="96796" xml_f="96802" txt_i="29268" txt_f="29274">Hunger</offsets></td><td char="(" id="dom12779-ent-0507" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="96893" xml_f="96900" txt_i="29275" txt_f="29282">1 (4.0)</offsets></td><td char="(" id="dom12779-ent-0508" align="char" valign="top" rowspan="1" colspan="1"><offsets xml_i="96991" xml_f="96999" txt_i="29283" txt_f="29291">3 (12.0)</offsets></td><td id="dom12779-ent-0509" align="char" valign="top" rowspan="1" colspan="1"></td><td id="dom12779-ent-0510" align="char" valign="top" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="dom12779-note-0020"><label><offsets xml_i="97241" xml_f="97242" txt_i="29294" txt_f="29295">a</offsets></label><p><offsets xml_i="97253" xml_f="97318" txt_i="29295" txt_f="29360">Assessed using the Modification of Diet in Renal Disease formula.</offsets></p></fn><fn id="dom12779-note-0021"><label><offsets xml_i="97362" xml_f="97363" txt_i="29361" txt_f="29362">b</offsets></label><p><offsets xml_i="97374" xml_f="97383" txt_i="29362" txt_f="29371">Data are </offsets><styled-content style="fixed-case"><offsets xml_i="97418" xml_f="97420" txt_i="29371" txt_f="29373">LS</offsets></styled-content><offsets xml_i="97437" xml_f="97485" txt_i="29373" txt_f="29421"> mean changes from baseline to 24 weeks and 95% </offsets><styled-content style="fixed-case"><offsets xml_i="97520" xml_f="97522" txt_i="29421" txt_f="29423">CI</offsets></styled-content><offsets xml_i="97539" xml_f="97663" txt_i="29423" txt_f="29547">s derived from a mixed model for repeated measures adjusted for treatment, week, treatment‐by‐week, sex, and baseline value.</offsets></p></fn><fn id="dom12779-note-0022"><label><offsets xml_i="97707" xml_f="97708" txt_i="29548" txt_f="29549">c</offsets></label><p><offsets xml_i="97719" xml_f="97728" txt_i="29549" txt_f="29558">Data are </offsets><styled-content style="fixed-case"><offsets xml_i="97763" xml_f="97765" txt_i="29558" txt_f="29560">LS</offsets></styled-content><offsets xml_i="97782" xml_f="97830" txt_i="29560" txt_f="29608"> mean changes from baseline to 24 weeks and 95% </offsets><styled-content style="fixed-case"><offsets xml_i="97865" xml_f="97867" txt_i="29608" txt_f="29610">CI</offsets></styled-content><offsets xml_i="97884" xml_f="97979" txt_i="29610" txt_f="29705">s derived from an analysis of covariance model adjusted for treatment, sex, and baseline value.</offsets></p></fn><fn id="dom12779-note-0023"><label><offsets xml_i="98023" xml_f="98024" txt_i="29706" txt_f="29707">d</offsets></label><p><offsets xml_i="98035" xml_f="98036" txt_i="29707" txt_f="29708">
</offsets><styled-content style="fixed-case"><offsets xml_i="98071" xml_f="98073" txt_i="29708" txt_f="29710">AE</offsets></styled-content><offsets xml_i="98090" xml_f="98275" txt_i="29710" txt_f="29895">s of special interest for dapagliflozin and exenatide (e.g. urinary tract and genital infections and vomiting, nausea, and diarrhoea, respectively) were coded using predefined lists of </offsets><styled-content style="fixed-case"><offsets xml_i="98310" xml_f="98316" txt_i="29895" txt_f="29901">MedDRA</offsets></styled-content><offsets xml_i="98333" xml_f="98363" txt_i="29901" txt_f="29931"> version 18.0 preferred terms.</offsets></p></fn></table-wrap-foot></table-wrap><p id="dom12779-para-0038"><offsets xml_i="98430" xml_f="98479" txt_i="29932" txt_f="29981">All participants reported at least one AE (Table </offsets><xref rid="dom12779-tbl-0003" ref-type="table-wrap"><offsets xml_i="98531" xml_f="98532" txt_i="29981" txt_f="29982">3</offsets></xref><offsets xml_i="98539" xml_f="99107" txt_i="29982" txt_f="30550">). Serious AEs occurred in two participants [hospitalization from head trauma (dapagliflozin/exenatide) and hospitalization because of dyspnoea (placebo)]. No deaths occurred. The most common AEs occurring in dapagliflozin/exenatide‐ and placebo‐treated participants, respectively, were nasopharyngitis, nine (36.0%) and four (16.0%), headache, eight (32.0%) and four (16.0%), and decreased appetite, eight (32.0%) and three (12.0%). No participant experienced confirmed hypoglycaemia. One placebo‐treated participant was diagnosed with T2D at the final 24‐week visit.</offsets></p><p id="dom12779-para-0039"><offsets xml_i="99138" xml_f="99378" txt_i="30551" txt_f="30791">Urinary tract infections or genital infections were reported in three participants receiving dapagliflozin/exenatide and one participant receiving placebo; no participants reported AEs potentially related to renal impairment/failure (Table </offsets><xref rid="dom12779-tbl-0003" ref-type="table-wrap"><offsets xml_i="99430" xml_f="99431" txt_i="30791" txt_f="30792">3</offsets></xref><offsets xml_i="99438" xml_f="99440" txt_i="30792" txt_f="30794">).</offsets></p><p id="dom12779-para-0040"><offsets xml_i="99471" xml_f="99967" txt_i="30795" txt_f="31291">Gastrointestinal and injection‐site‐related AEs were more common with dapagliflozin/exenatide than placebo. Gastrointestinal AEs occurred in 16 (64.0%) and 10 (40.0%) of dapagliflozin/exenatide‐ and placebo‐treated participants, respectively; nausea was the most frequent, occurring in seven (28.0%) and three (12.0%) participants, respectively. Injection‐site‐related AEs occurred in 11 (44.0%) and eight (32.0%) of dapagliflozin/exenatide‐ and placebo‐treated participants, respectively (Table </offsets><xref rid="dom12779-tbl-0003" ref-type="table-wrap"><offsets xml_i="100019" xml_f="100020" txt_i="31291" txt_f="31292">3</offsets></xref><offsets xml_i="100027" xml_f="100029" txt_i="31292" txt_f="31294">).</offsets></p></sec></sec><sec id="dom12779-sec-0022"><label><offsets xml_i="100080" xml_f="100081" txt_i="31297" txt_f="31298">4</offsets></label><title><offsets xml_i="100096" xml_f="100106" txt_i="31298" txt_f="31308">DISCUSSION</offsets></title><p id="dom12779-para-0041"><offsets xml_i="100141" xml_f="101348" txt_i="31309" txt_f="32516">Classes of glucose‐lowering agents for T2D treatment that reduce body weight include SGLT2 inhibitors and GLP‐1RAs. These two drug classes have rarely been evaluated together in T2D trials and their dual effects on body weight loss have not been previously studied in obese adults without diabetes. The results of the present study showed that dual therapy with dapagliflozin 10 mg once daily and exenatide 2 mg once weekly significantly reduced body weight in obese adults without diabetes over 24 weeks of follow‐up, with most changes observed during the first 12 weeks. Among dapagliflozin/exenatide‐treated participants, 36.0% lost ≥5% and 12.0% lost ≥10% of their initial weight. MRI showed that body weight loss was primarily adipose rather than lean tissue, with an average total adipose tissue loss of 4.09 L. HbA1c, FPG and the proportion of participants with prediabetes were also improved with dapagliflozin/exenatide versus placebo. Dapagliflozin/exenatide reduced SBP by −6.7 mm Hg versus placebo over 24 weeks. Dapagliflozin/exenatide was well tolerated with a side‐effect profile consistent with that observed in trials of the individual agents. No unexpected safety concerns were identified.</offsets></p><p id="dom12779-para-0042"><offsets xml_i="101379" xml_f="101521" txt_i="32517" txt_f="32659">Body weight loss observed after dual therapy appeared to be greater than for dapagliflozin and exenatide individually in previous T2D studies,</offsets><xref rid="dom12779-bib-0012" ref-type="ref"><offsets xml_i="101566" xml_f="101568" txt_i="32659" txt_f="32661">12</offsets></xref><offsets xml_i="101575" xml_f="101577" txt_i="32661" txt_f="32663">, </offsets><xref rid="dom12779-bib-0021" ref-type="ref"><offsets xml_i="101622" xml_f="101624" txt_i="32663" txt_f="32665">21</offsets></xref><offsets xml_i="101631" xml_f="101873" txt_i="32665" txt_f="32907"> and these drugs may have contributed additively to the observed body weight loss. Dapagliflozin reduces body weight via increased calorie expenditure through the urine; however, this calorie loss can lead to a compensatory appetite increase.</offsets><xref rid="dom12779-bib-0008" ref-type="ref"><offsets xml_i="101918" xml_f="101919" txt_i="32907" txt_f="32908">8</offsets></xref><offsets xml_i="101926" xml_f="102031" txt_i="32908" txt_f="33013"> In contrast, exenatide reduces appetite and delays gastric emptying, which both lead to bodyweight loss.</offsets><xref rid="dom12779-bib-0028" ref-type="ref"><offsets xml_i="102076" xml_f="102078" txt_i="33013" txt_f="33015">28</offsets></xref><offsets xml_i="102085" xml_f="102296" txt_i="33015" txt_f="33226"> Used together, the mechanisms of the two drugs may have complemented each other; however, the potential for an additive effect cannot be evaluated because this trial did not contain monotherapy comparator arms.</offsets></p><p id="dom12779-para-0043"><offsets xml_i="102327" xml_f="102789" txt_i="33227" txt_f="33689">The combination of a selective SGLT2 inhibitor and a GLP‐1RA initiated together has not been studied previously, but available data on sequential addition of these drug classes in patients with T2D support this treatment approach. In the randomized, double‐blind, placebo‐controlled CANVAS study, patients failing treatment for diabetes with an incretin mimetic (dipeptidyl peptidase‐4 inhibitor or GLP‐1RA) received the SGLT2 inhibitor canagliflozin or placebo.</offsets><xref rid="dom12779-bib-0029" ref-type="ref"><offsets xml_i="102834" xml_f="102836" txt_i="33689" txt_f="33691">29</offsets></xref><offsets xml_i="102843" xml_f="103084" txt_i="33691" txt_f="33932"> After 18 weeks, placebo‐subtracted reductions in body weight were −2.7 and −3.3 kg with canagliflozin 100 and 300 mg, respectively, both added to a GLP‐1RA. HbA1c and SBP were also reduced for both doses of canagliflozin added to a GLP‐1RA.</offsets></p><p id="dom12779-para-0044"><offsets xml_i="103115" xml_f="103615" txt_i="33933" txt_f="34433">Ongoing clinical trials investigating the SGLT2 inhibitor/GLP‐1RA combination initiated together in patients with T2D will provide important information on body weight loss in T2D. These include DURATION‐8 (NCT02229396), evaluating exenatide 2 mg once weekly and dapagliflozin 10 mg once daily, administered as single agents and as dual therapy in patients withT2D with inadequate glycaemic control on metformin, and AWARD‐10 (NCT02597049), evaluating empagliflozin added sequentially to dulaglutide.</offsets></p><p id="dom12779-para-0045"><offsets xml_i="103646" xml_f="104239" txt_i="34434" txt_f="35027">Identification of the type of tissue lost during treatment with dapagliflozin/exenatide is important because lean tissue loss would be less beneficial to obese adults than adipose tissue loss, in particular visceral or ectopic fat deposits. In the present study, compared with placebo, dapagliflozin/exenatide treatment significantly reduced subcutaneous and visceral abdominal adipose tissue (but not lean tissue). An earlier study indicated that the body weight lost with dapagliflozin 10 mg once daily added to metformin in patients with T2D was two‐thirds fat mass and one‐third lean mass.</offsets><xref rid="dom12779-bib-0014" ref-type="ref"><offsets xml_i="104284" xml_f="104286" txt_i="35027" txt_f="35029">14</offsets></xref><offsets xml_i="104293" xml_f="104534" txt_i="35029" txt_f="35270"> A study in which immediate‐release exenatide was added to metformin found that body weight loss over 1 year with this combination reduced total fat mass by −11% (approximately −2.4 kg) among 29 patients with T2D without affecting lean mass.</offsets><xref rid="dom12779-bib-0022" ref-type="ref"><offsets xml_i="104579" xml_f="104581" txt_i="35270" txt_f="35272">22</offsets></xref><offsets xml_i="104588" xml_f="104674" txt_i="35272" txt_f="35358"> Exenatide treatment has also been reported to reduce liver fat over 6 months by −18%.</offsets><xref rid="dom12779-bib-0030" ref-type="ref"><offsets xml_i="104719" xml_f="104721" txt_i="35358" txt_f="35360">30</offsets></xref><offsets xml_i="104728" xml_f="105177" txt_i="35360" txt_f="35809"> The adipose tissue reductions found in this study are generally compatible with previous observations of dapagliflozin and exenatide individually, although the numeric reduction in liver fat with dapagliflozin/exenatide was not significantly different from placebo. Because the present study was not powered to detect differences in liver fat, this merits further exploration, e.g. in populations with more pronounced hepatic steatosis at baseline.</offsets></p><p id="dom12779-para-0046"><offsets xml_i="105208" xml_f="105511" txt_i="35810" txt_f="36113">Hypertension is a frequent comorbidity of obesity and diabetes and an important part of metabolic syndrome. Improving blood pressure control is a common clinical goal for obese patients. Individually, dapagliflozin 10 mg once daily has been associated with SBP reductions ranging from −2.6 to −3.6 mm Hg</offsets><xref rid="dom12779-bib-0031" ref-type="ref"><offsets xml_i="105556" xml_f="105558" txt_i="36113" txt_f="36115">31</offsets></xref><offsets xml_i="105565" xml_f="105676" txt_i="36115" txt_f="36226"> and exenatide (pooled data of immediate‐ and extended‐release preparations) with SBP reductions of −1.8 mm Hg.</offsets><xref rid="dom12779-bib-0032" ref-type="ref"><offsets xml_i="105721" xml_f="105723" txt_i="36226" txt_f="36228">32</offsets></xref><offsets xml_i="105730" xml_f="105903" txt_i="36228" txt_f="36401"> Importantly, the observed reduction in SBP of −6.7 mm Hg in the present study was larger than would have been expected from either drug component administered individually.</offsets><xref rid="dom12779-bib-0031" ref-type="ref"><offsets xml_i="105948" xml_f="105950" txt_i="36401" txt_f="36403">31</offsets></xref><offsets xml_i="105957" xml_f="105959" txt_i="36403" txt_f="36405">, </offsets><xref rid="dom12779-bib-0032" ref-type="ref"><offsets xml_i="106004" xml_f="106006" txt_i="36405" txt_f="36407">32</offsets></xref><offsets xml_i="106013" xml_f="106101" txt_i="36407" txt_f="36495"> Dapagliflozin can reduce SBP via several mechanisms, including reduction in body weight</offsets><xref rid="dom12779-bib-0009" ref-type="ref"><offsets xml_i="106146" xml_f="106147" txt_i="36495" txt_f="36496">9</offsets></xref><offsets xml_i="106154" xml_f="106202" txt_i="36496" txt_f="36544"> and increased osmotic diuresis and natriuresis.</offsets><xref rid="dom12779-bib-0010" ref-type="ref"><offsets xml_i="106247" xml_f="106249" txt_i="36544" txt_f="36546">10</offsets></xref><offsets xml_i="106256" xml_f="106354" txt_i="36546" txt_f="36644"> The mechanism by which exenatide reduces SBP is less well understood but may involve vasodilation</offsets><xref rid="dom12779-bib-0033" ref-type="ref"><offsets xml_i="106399" xml_f="106401" txt_i="36644" txt_f="36646">33</offsets></xref><offsets xml_i="106408" xml_f="106428" txt_i="36646" txt_f="36666"> and/or natriuresis.</offsets><xref rid="dom12779-bib-0034" ref-type="ref"><offsets xml_i="106473" xml_f="106475" txt_i="36666" txt_f="36668">34</offsets></xref><offsets xml_i="106482" xml_f="106703" txt_i="36668" txt_f="36889"> Thus, the SBP‐lowering mechanisms of exenatide may complement or augment dapagliflozin‐induced plasma volume reduction. Notably, no hypotension or dehydration was reported in dapagliflozin/exenatide‐treated participants.</offsets></p><p id="dom12779-para-0047"><offsets xml_i="106734" xml_f="107303" txt_i="36890" txt_f="37459">This study was too small to identify uncommon AEs. Nevertheless, no new safety findings, and no marked increase in discontinuations or expected AEs, were observed with SGLT2 inhibitor/GLP‐1RA dual therapy. Urinary tract infections (n = 2; 8.0%), genital infections (n = 1; 4.0%), and renal AEs (0%) were infrequent with dapagliflozin/exenatide but, as anticipated, nausea, injection‐site mass, and injection‐site pruritus appeared more frequent with dapagliflozin/exenatide (28.0%, 28.0% and 28.0%, respectively) than with placebo (12.0%, 20.0% and 8.0%, respectively).</offsets></p><p id="dom12779-para-0048"><offsets xml_i="107334" xml_f="107960" txt_i="37460" txt_f="38086">Use of a high‐dose GLP‐1RA has been suggested as an alternative to combination pharmacotherapy for body weight loss, but the incidence of AEs and need for additional injections may limit its use. Liraglutide has been approved as a body weight loss therapy at a higher dose (3 mg once daily) than used to treat T2D (1.8 mg once daily). In a placebo‐controlled study in obese participants without diabetes receiving liraglutide 3 mg once daily, body weight loss and relative reductions in prediabetes prevalence with liraglutide appeared to be similar to those observed in the present study, but nausea occurred more frequently.</offsets><xref rid="dom12779-bib-0035" ref-type="ref"><offsets xml_i="108005" xml_f="108007" txt_i="38086" txt_f="38088">35</offsets></xref><offsets xml_i="108014" xml_f="108146" txt_i="38088" txt_f="38220"> Interestingly, dapagliflozin/exenatide dual therapy at higher doses may provide additional body weight loss and metabolic benefits.</offsets></p><p id="dom12779-para-0049"><offsets xml_i="108177" xml_f="108886" txt_i="38221" txt_f="38930">The present study has some limitations. It was a small, short‐term, single‐centre, proof‐of‐concept study with no monotherapy comparator groups, which are needed to formally evaluate whether effects with dapagliflozin/exenatide on body weight loss, glycaemic control and SBP are additive. Body weight responses to dapagliflozin/exenatide varied between individuals and further research is required to identify behaviours or biomarkers predicting response to dapagliflozin/exenatide. Moreover, different results might be observed in patients undergoing intensive lifestyle intervention. The study was conducted in participants without diabetes, and results cannot be directly extrapolated to patients with T2D.</offsets></p><p id="dom12779-para-0050"><offsets xml_i="108917" xml_f="109361" txt_i="38931" txt_f="39375">In summary, this proof‐of‐concept study shows that dapagliflozin/exenatide reduces body weight, prediabetes occurrence and SBP compared with placebo and is well tolerated in an obese population without diabetes. These findings, together with the convenience of once‐daily oral dosing and once‐weekly injection, support further investigation to assess dapagliflozin/exenatide for body weight loss and prevention of diabetes in obese individuals.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="109417" xml_f="109439" txt_i="39377" txt_f="39399">Supporting information</offsets></title><supplementary-material content-type="local-data" id="dom12779-supitem-0001"><caption><p><offsets xml_i="109536" xml_f="109537" txt_i="39400" txt_f="39401">
</offsets><bold><offsets xml_i="109543" xml_f="109551" txt_i="39401" txt_f="39409">File S1.</offsets></bold><offsets xml_i="109558" xml_f="109681" txt_i="39409" txt_f="39532"> Inclusion/Exclusion Criteria; MRI methods; OGTT methods; sample size calculations; Table S1 (other laboratory parameters).</offsets></p></caption><media xlink:href="DOM-19-49-s001.docx"><caption><p><offsets xml_i="109747" xml_f="109783" txt_i="39533" txt_f="39569">Click here for additional data file.</offsets></p></caption></media></supplementary-material></sec></body><back><ack id="dom12779-sec-0023"><title>ACKNOWLEDGMENTS</title><p id="dom12779-para-0051">This study was supported by AstraZeneca. Julian Martins of inScience Communications, Springer Healthcare, provided medical writing support funded by AstraZeneca. Mary Beth DeYoung and Elise Hardy of AstraZeneca critically reviewed the manuscript.</p><p id="dom12779-para-0052">We thank Uppsala University Hospital and Uppsala University for assistance with the study conduct and data collection, Pharmaconsulting Group Clinical Services AB for support of study conduct, data management and analyses, and Antaros Medical AB for MRI analyses.</p><p id="dom12779-para-0053">Prior presentation: This study has been published previously in abstract form in the following publication: Eriksson JW, Lundkvist P, Amini S, et al. Dapagliflozin + Exenatide once weekly Reduced Body Weight and Improved Glucose Tolerance in Nondiabetic Obese Adults: a Randomized Placebo‐Controlled Phase 2 Study. Presented at the 76th Scientific Sessions of the American Diabetes Association, 10–14 June, 2016, New Orleans, Louisiana, USA.</p><sec id="dom12779-sec-0024"><title>Conflict of interest</title><p id="dom12779-para-0054">J. W. E. has received research grants or honoraria from AstraZeneca, Bristol‐Myers Squibb, Merck Sharp &amp; Dohme, NovoNordisk, and Sanofi. P. L., S. A., and M. J. P. have no conflicts of interest to declare. C. D. S. and E. J. are employees of and own stock in AstraZeneca.</p></sec><sec id="dom12779-sec-0025"><title>Author contributions</title><p id="dom12779-para-0055">P. L. contributed to the conduct of the study, interpreting and discussing results, writing the manuscript, and critically revising all subsequent versions. C. D. S. and E. J. contributed to interpreting and discussing results, writing the manuscript, and critically revising all subsequent versions. S. A. contributed to the conduct of the study and to critically revising all versions of the manuscript. M. J. P. contributed to the design and conduct of the study, interpreting and discussing results, writing the manuscript, and critically revising all subsequent versions. J. W. E. designed the study, contributed to the conduct of the study, interpreting and discussing results, writing the manuscript, and critically revising all versions of the manuscript.</p></sec></ack><ref-list content-type="cited-references" id="dom12779-bibl-0001"><title>REFERENCES</title><ref id="dom12779-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="dom12779-cit-0001">
<collab collab-type="authors" id="dom12779-gp-0001">World Health Organization</collab>
. <article-title>Obesity and overweight: fact sheet no. 311</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs311/en/">http://www.who.int/mediacentre/factsheets/fs311/en/</ext-link>. Last updated June 2016. Accessed 09 September 2016</mixed-citation></ref><ref id="dom12779-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12779-cit-0003">
<string-name>
<surname>Norris</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Avenell</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gregg</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Lau</surname>
<given-names>J</given-names>
</string-name>. <article-title>Long‐term non‐pharmacological weight loss interventions for adults with prediabetes</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2005</year>: Issue 2. Art. No.: CD005270. DOI: <ext-link ext-link-type="doi" xlink:href="10.1002/14651858.CD005270">10.1002/14651858.CD005270</ext-link>.</mixed-citation></ref><ref id="dom12779-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12779-cit-0004">
<string-name>
<surname>Norris</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Avenell</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Long‐term non‐pharmacologic weight loss interventions for adults with type 2 diabetes</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2005</year>: Issue 2. Art. No.: CD004095. DOI: <ext-link ext-link-type="doi" xlink:href="10.1002/14651858.CD004095.pub2">10.1002/14651858.CD004095.pub2</ext-link>.</mixed-citation></ref><ref id="dom12779-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12779-cit-0005">
<string-name>
<surname>Apovian</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Aronne</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Bessesen</surname>
<given-names>DH</given-names>
</string-name>, et al. <article-title>Pharmacological management of obesity: an Endocrine Society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metabol</source>. <year>2015</year>;<volume>100</volume>:<fpage>342</fpage>‐<lpage>362</lpage>.</mixed-citation></ref><ref id="dom12779-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12779-cit-0006">
<string-name>
<surname>Morgan</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Jenkins‐Jones</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barnett</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Poole</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Currie</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs</article-title>. <source>Diabetes Obes Metab</source>. <year>2012</year>;<volume>14</volume>:<fpage>424</fpage>‐<lpage>432</lpage>.<pub-id pub-id-type="pmid">22192841</pub-id></mixed-citation></ref><ref id="dom12779-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12779-cit-0007">
<string-name>
<surname>Monami</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nardini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mannucci</surname>
<given-names>E</given-names>
</string-name>. <article-title>Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>457</fpage>‐<lpage>466</lpage>.<pub-id pub-id-type="pmid">24320621</pub-id></mixed-citation></ref><ref id="dom12779-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12779-cit-0008">
<string-name>
<surname>van Bloemendaal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ten Kulve</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>la Fleur</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Ijzerman</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Diamant</surname>
<given-names>M</given-names>
</string-name>. <article-title>Effects of glucagon‐like peptide 1 on appetite and body weight: focus on the CNS</article-title>. <source>J Endocrinol</source>. <year>2014</year>;<volume>221</volume>:<fpage>T1</fpage>‐<lpage>T16</lpage>.<pub-id pub-id-type="pmid">24323912</pub-id></mixed-citation></ref><ref id="dom12779-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12779-cit-0009">
<string-name>
<surname>Ferrannini</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hach</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Crowe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sanghvi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>. <article-title>Energy balance after sodium‐glucose cotransporter 2 inhibition</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>1730</fpage>‐<lpage>1735</lpage>.<pub-id pub-id-type="pmid">26180105</pub-id></mixed-citation></ref><ref id="dom12779-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12779-cit-0010">
<string-name>
<surname>Sjostrom</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Hashemi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sugg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ptaszynska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Johnsson</surname>
<given-names>E</given-names>
</string-name>. <article-title>Dapagliflozin‐induced weight loss affects 24‐week glycated haemoglobin and blood pressure levels</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>809</fpage>‐<lpage>812</lpage>.<pub-id pub-id-type="pmid">25997813</pub-id></mixed-citation></ref><ref id="dom12779-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12779-cit-0011">
<string-name>
<surname>Lambers Heerspink</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>de Zeeuw</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wie</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Leslie</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>List</surname>
<given-names>J</given-names>
</string-name>. <article-title>Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2013</year>;<volume>15</volume>:<fpage>853</fpage>‐<lpage>862</lpage>.<pub-id pub-id-type="pmid">23668478</pub-id></mixed-citation></ref><ref id="dom12779-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12779-cit-0012">
<string-name>
<surname>Katout</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rutsky</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Effect of GLP‐1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta‐analysis and meta‐regression</article-title>. <source>Am J Hypertens</source>. <year>2014</year>;<volume>27</volume>:<fpage>130</fpage>‐<lpage>139</lpage>.<pub-id pub-id-type="pmid">24263424</pub-id></mixed-citation></ref><ref id="dom12779-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12779-cit-0013">
<string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jimenez Ramos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Salsali</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>List</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial</article-title>. <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>:<fpage>2217</fpage>‐<lpage>2224</lpage>.<pub-id pub-id-type="pmid">20566676</pub-id></mixed-citation></ref><ref id="dom12779-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12779-cit-0014">
<string-name>
<surname>Bailey</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Gross</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Pieters</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bastien</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>List</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double‐blind, placebo‐controlled trial</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>:<fpage>2223</fpage>‐<lpage>2233</lpage>.<pub-id pub-id-type="pmid">20609968</pub-id></mixed-citation></ref><ref id="dom12779-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12779-cit-0015">
<string-name>
<surname>Bolinder</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ljunggren</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Kullberg</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin</article-title>. <source>J Clin Endocrinol Metabol</source>. <year>2012</year>;<volume>97</volume>:<fpage>1020</fpage>‐<lpage>1031</lpage>.</mixed-citation></ref><ref id="dom12779-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12779-cit-0016">
<string-name>
<surname>Jabbour</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Hardy</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sugg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>S</given-names>
</string-name>. <article-title>Dapagliflozin is effective as add‐on therapy to sitagliptin with or without metformin: a 24‐week, multicenter, randomized, double‐blind, placebo‐controlled study</article-title>. <source>Diabetes Care</source>. <year>2014</year>;<volume>37</volume>:<fpage>740</fpage>‐<lpage>750</lpage>.<pub-id pub-id-type="pmid">24144654</pub-id></mixed-citation></ref><ref id="dom12779-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12779-cit-0017">
<string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vico</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Salsali</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>List</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy</article-title>. <source>Diabetes Care</source>. <year>2012</year>;<volume>35</volume>:<fpage>1473</fpage>‐<lpage>1478</lpage>.<pub-id pub-id-type="pmid">22446170</pub-id></mixed-citation></ref><ref id="dom12779-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12779-cit-0018">
<string-name>
<surname>Strojek</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Hruba</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Elze</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Langkilde</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>S</given-names>
</string-name>. <article-title>Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2011</year>;<volume>13</volume>:<fpage>928</fpage>‐<lpage>938</lpage>.<pub-id pub-id-type="pmid">21672123</pub-id></mixed-citation></ref><ref id="dom12779-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom12779-cit-0019">
<string-name>
<surname>Wilding</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Soler</surname>
<given-names>NG</given-names>
</string-name>, et al. <article-title>Long‐term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial</article-title>. <source>Ann Intern Med</source>. <year>2012</year>;<volume>156</volume>:<fpage>405</fpage>‐<lpage>415</lpage>.<pub-id pub-id-type="pmid">22431673</pub-id></mixed-citation></ref><ref id="dom12779-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12779-cit-0020">
<string-name>
<surname>Zaccardi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Htike</surname>
<given-names>ZZ</given-names>
</string-name>, <string-name>
<surname>Youssef</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Khunti</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>MJ</given-names>
</string-name>. <article-title></article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>783</fpage>‐<lpage>794</lpage>.<pub-id pub-id-type="pmid">27059700</pub-id></mixed-citation></ref><ref id="dom12779-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12779-cit-0021">
<string-name>
<surname>Bolinder</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ljunggren</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>159</fpage>‐<lpage>169</lpage>.<pub-id pub-id-type="pmid">23906445</pub-id></mixed-citation></ref><ref id="dom12779-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom12779-cit-0024">
<string-name>
<surname>Potts</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Gray</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Brady</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Khunti</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bodicoat</surname>
<given-names>DH</given-names>
</string-name>. <article-title>The effect of glucagon‐like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta‐analysis</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0126769</fpage>.<pub-id pub-id-type="pmid">26121478</pub-id></mixed-citation></ref><ref id="dom12779-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom12779-cit-0025">
<string-name>
<surname>Bunck</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Diamant</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eliasson</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition</article-title>. <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>:<fpage>1734</fpage>‐<lpage>1737</lpage>.<pub-id pub-id-type="pmid">20424219</pub-id></mixed-citation></ref><ref id="dom12779-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom12779-cit-0026">
<string-name>
<surname>Diamant</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Van Gaal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Guerci</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION‐3): 3‐year results of an open‐label randomised trial</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2014</year>;<volume>2</volume>:<fpage>464</fpage>‐<lpage>473</lpage>.<pub-id pub-id-type="pmid">24731672</pub-id></mixed-citation></ref><ref id="dom12779-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom12779-cit-0027">
<string-name>
<surname>Wysham</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>MacConell</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Maggs</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Trautmann</surname>
<given-names>ME</given-names>
</string-name>. <article-title>Five‐year efficacy and safety data of exenatide once weekly: long‐term results from the DURATION‐1 randomized clinical trial</article-title>. <source>Mayo Clin Proc</source>. <year>2015</year>;<volume>90</volume>:<fpage>356</fpage>‐<lpage>365</lpage>.<pub-id pub-id-type="pmid">25744115</pub-id></mixed-citation></ref><ref id="dom12779-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom12779-cit-0028">
<string-name>
<surname>Leibel</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Rosenbaum</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hirsch</surname>
<given-names>J</given-names>
</string-name>. <article-title>Changes in energy expenditure resulting from altered body weight</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>332</volume>:<fpage>621</fpage>‐<lpage>628</lpage>.<pub-id pub-id-type="pmid">7632212</pub-id></mixed-citation></ref><ref id="dom12779-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dom12779-cit-0029">
<string-name>
<surname>Yanovski</surname>
<given-names>SZ</given-names>
</string-name>, <string-name>
<surname>Yanovski</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Long‐term drug treatment for obesity: a systematic and clinical review</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>311</volume>:<fpage>74</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">24231879</pub-id></mixed-citation></ref><ref id="dom12779-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dom12779-cit-0030">
<string-name>
<surname>Levey</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Bosch</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Greene</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Roth</surname>
<given-names>D</given-names>
</string-name>. <article-title>A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group</article-title>. <source>Ann Intern Med</source>. <year>1999</year>;<volume>130</volume>:<fpage>461</fpage>‐<lpage>470</lpage>.<pub-id pub-id-type="pmid">10075613</pub-id></mixed-citation></ref><ref id="dom12779-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dom12779-cit-0031">
<string-name>
<surname>Bhavsar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mudaliar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cherrington</surname>
<given-names>A</given-names>
</string-name>. <article-title>Evolution of exenatide as a diabetes therapeutic</article-title>. <source>Curr Diabetes Rev</source>. <year>2013</year>;<volume>9</volume>:<fpage>161</fpage>‐<lpage>193</lpage>.<pub-id pub-id-type="pmid">23256660</pub-id></mixed-citation></ref><ref id="dom12779-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dom12779-cit-0032">
<string-name>
<surname>Fulcher</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Matthews</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Perkovic</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>82</fpage>‐<lpage>91</lpage>.<pub-id pub-id-type="pmid">26450639</pub-id></mixed-citation></ref><ref id="dom12779-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dom12779-cit-0033">
<string-name>
<surname>Cuthbertson</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Irwin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gardner</surname>
<given-names>CJ</given-names>
</string-name>, et al. <article-title>Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon‐like peptide‐1 (GLP‐1) receptor agonists</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e50117</fpage>.<pub-id pub-id-type="pmid">23236362</pub-id></mixed-citation></ref><ref id="dom12779-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dom12779-cit-0034">
<string-name>
<surname>Sjostrom</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ptaszynska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>List</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Johnsson</surname>
<given-names>E</given-names>
</string-name>. <article-title>Dapagliflozin lowers blood pressure in hypertensive and non‐hypertensive patients with type 2 diabetes</article-title>. <source>Diab Vasc Dis Res</source>. <year>2015</year>;<volume>12</volume>:<fpage>352</fpage>‐<lpage>358</lpage>.<pub-id pub-id-type="pmid">26008804</pub-id></mixed-citation></ref><ref id="dom12779-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dom12779-cit-0035">
<string-name>
<surname>Robinson</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Holt</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Rees</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Randeva</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>O'Hare</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta‐analysis</article-title>. <source>BMJ Open</source>. <year>2013</year>;<volume>3</volume>: e001986 doi:<ext-link ext-link-type="doi" xlink:href="10.1136/bmjopen-2012-001986">10.1136/bmjopen-2012-001986</ext-link>.</mixed-citation></ref><ref id="dom12779-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dom12779-cit-0036">
<string-name>
<surname>Irace</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>De Luca</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shehaj</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research</article-title>. <source>Diab Vasc Dis Res</source>. <year>2013</year>;<volume>10</volume>:<fpage>72</fpage>‐<lpage>77</lpage>.<pub-id pub-id-type="pmid">22732108</pub-id></mixed-citation></ref><ref id="dom12779-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dom12779-cit-0037">
<string-name>
<surname>Mendis</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>MacDonald</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mansell</surname>
<given-names>P</given-names>
</string-name>. <article-title>Investigation of the haemodynamic effects of exenatide in healthy male subjects</article-title>. <source>Br J Clin Pharmacol</source>. <year>2012</year>;<volume>74</volume>:<fpage>437</fpage>‐<lpage>444</lpage>.<pub-id pub-id-type="pmid">22320349</pub-id></mixed-citation></ref><ref id="dom12779-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dom12779-cit-0038">
<string-name>
<surname>Astrup</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rossner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Van Gaal</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Effects of liraglutide in the treatment of obesity: a randomised, double‐blind, placebo‐controlled study</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>374</volume>:<fpage>1606</fpage>‐<lpage>1616</lpage>.<pub-id pub-id-type="pmid">19853906</pub-id></mixed-citation></ref></ref-list></back></article>